QuidelOrtho 10-K 27 Feb 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 20, 2014	Jun. 30, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'QDEL	'	'
Entity Registrant Name	'QUIDEL CORP /DE/	'	'
Entity Central Index Key	'0000353569	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'Yes	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Large Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	34,088,516	'
Entity Public Float	'	'	$720,374,827

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$8,388	$14,856
Accounts receivable, net	29,928	32,570
Inventories	27,639	15,496
Deferred tax asset-current	8,362	6,622
Prepaid expenses and other current assets	4,302	5,228
Total current assets	78,619	74,772
Property, plant and equipment, net	48,057	34,156
Goodwill	80,763	71,013
Intangible assets, net	62,262	60,341
Other non-current assets	1,784	1,817
Total assets	271,485	242,099
Current liabilities:	'	'
Accounts payable	6,950	7,864
Accrued payroll and related expenses	7,485	6,016
Current portion of lease obligation	441	380
Current portion of contingent consideration (see Note 10)	1,493	'
Other current liabilities	7,640	8,241
Total current liabilities	24,009	22,501
Long term debt	'	5,000
Lease obligation, net of current portion	5,126	5,567
Contingent consideration-non-current (see Note 10)	7,315	'
Deferred tax liability-non-current	6,318	3,349
Income taxes payable	2,118	4,548
Other non-current liabilities	2,820	1,354
Commitments and contingencies (see Note 6)	'	'
Stockholders' equity:	'	'
Preferred stock, $.001 par value per share; 5,000 shares authorized; none issued or outstanding at December 31, 2013 and 2012	'	'
Common stock, $.001 par value per share; 50,000 shares authorized; 34,073 and 33,451 shares issued and outstanding at December 31, 2013 and 2012, respectively	34	33
Additional paid-in capital	201,021	184,431
Accumulated other comprehensive income	18	'
Retained earnings	22,706	15,316
Total stockholders' equity	223,779	199,780
Total liabilities and stockholders' equity	$271,485	$242,099

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Per Share data, unless otherwise specified
Statement Of Financial Position [Abstract]	'	'
Preferred stock, par value per share	$0.00	$0.00
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued	'	'
Preferred stock, shares outstanding	'	'
Common stock, par value per share	$0.00	$0.00
Common stock, shares authorized	50,000	50,000
Common stock, shares issued	34,073	33,451
Common stock, shares outstanding	34,073	33,451

Consolidated_Statements_of_Inc

Consolidated Statements of Income (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Statement [Abstract]	'	'	'
Total revenues	$175,410	$155,741	$158,603
Costs and expenses	'	'	'
Cost of sales (excludes amortization of intangible assets of $6,079, $5,753, and $6,667, respectively)	66,976	61,285	62,865
Research and development	34,186	27,716	26,325
Sales and marketing	33,829	30,319	25,751
General and administrative	26,258	20,640	22,798
Amortization of intangible assets from acquired businesses and technology	8,171	6,935	7,124
Facility restructuring charges	1,825	'	'
Total costs and expenses	171,245	146,895	144,863
Operating income	4,165	8,846	13,740
Other (expense) income	'	'	'
Interest income	15	41	203
Interest expense	-777	-1,246	-2,083
Other income (expense)	31	-30	-376
Total other expense	-731	-1,235	-2,256
Income before (benefit) provision for income taxes	3,434	7,611	11,484
(Benefit) provision for income taxes	-3,956	2,618	3,851
Net income	$7,390	$4,993	$7,633
Basic earnings per share	$0.22	$0.15	$0.23
Diluted earnings per share	$0.21	$0.15	$0.23
Shares used in basic per share calculations	33,836	33,068	32,903
Shares used in diluted per share calculations	34,947	33,702	33,320

Consolidated_Statements_of_Inc1

Consolidated Statements of Income (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Statement [Abstract]	'	'	'
Amortization of intangible assets	$6,079	$5,753	$6,667

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement Of Income And Comprehensive Income [Abstract]	'	'	'
Net income	$7,390	$4,993	$7,633
Other comprehensive income, net of tax	'	'	'
Changes in cumulative translation adjustment	18	'	'
Comprehensive income	$7,408	$4,993	$7,633

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Common stock additional paid-in capital [Member]	Accumulated other comprehensive income [Member]	Retained Earnings [Member]
In Thousands
Beginning Balance at Dec. 31, 2010	$112,521	$29	$109,802	'	$2,690
Beginning Balance, shares at Dec. 31, 2010	'	28,514	'	'	'
Issuance of common stock under equity compensation plans	2,018	'	2,018	'	'
Issuance of common stock under equity compensation plans, shares	'	236	'	'	'
Issuance of common stock through public offering	57,225	5	57,220	'	'
Issuance of common stock through public offering, shares	'	4,600	'	'	'
Cancellation of common stock under equity compensation plans	-1	-1	'	'	'
Cancellation of common stock under equity compensation plans, shares	'	-31	'	'	'
Income tax benefit due to exercise/disposition of employee stock options	12	'	12	'	'
Stock-based compensation expense	6,603	'	6,603	'	'
Repurchase of common stock	-625	'	-625	'	'
Repurchase of common stock, shares	'	-43	'	'	'
Net income	7,633	'	'	'	7,633
Ending Balance at Dec. 31, 2011	185,386	33	175,030	'	10,323
Ending Balance, shares at Dec. 31, 2011	'	33,276	'	'	'
Issuance of common stock under equity compensation plans	5,581	'	5,581	'	'
Issuance of common stock under equity compensation plans, shares	'	415	'	'	'
Cancellation of common stock under equity compensation plans, shares	'	-9	'	'	'
Income tax benefit due to exercise/disposition of employee stock options	1,102	'	1,102	'	'
Stock-based compensation expense	6,125	'	6,125	'	'
Repurchase of common stock	-3,407	'	-3,407	'	'
Repurchase of common stock, shares	'	-231	'	'	'
Net income	4,993	'	'	'	4,993
Ending Balance at Dec. 31, 2012	199,780	33	184,431	'	15,316
Ending Balance, shares at Dec. 31, 2012	'	33,451	'	'	'
Issuance of common stock under equity compensation plans	8,385	1	8,384	'	'
Issuance of common stock under equity compensation plans, shares	'	708	'	'	'
Income tax benefit due to exercise/disposition of employee stock options	2,346	'	2,346	'	'
Stock-based compensation expense	8,017	'	8,017	'	'
Repurchase of common stock	-2,157	'	-2,157	'	'
Repurchase of common stock, shares	'	-86	'	'	'
Changes in cumulative translation adjustment, net of tax	18	'	'	18	'
Net income	7,390	'	'	'	7,390
Ending Balance at Dec. 31, 2013	$223,779	$34	$201,021	$18	$22,706
Ending Balance, shares at Dec. 31, 2013	'	34,073	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
OPERATING ACTIVITIES	'	'	'
Net income	$7,390	$4,993	$7,633
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'
Depreciation, amortization and other	24,694	23,261	17,809
Stock-based compensation expense	8,771	6,598	7,500
Impairment of intangible assets	'	'	1,643
Loss on disposal of assets	202	101	368
Change in fair value of acquisition contingency	80	'	'
Change in deferred tax assets and liabilities	-1,928	1,469	1,217
Excess tax benefit from share-based compensation	-2,346	-1,102	-12
Changes in assets and liabilities:	'	'	'
Accounts receivable	2,911	-17,924	-1,169
Inventories	-11,975	-1,075	3,401
Prepaid expenses and other current and non-current assets	1,136	-1,875	7,837
Accounts payable	-651	1,545	126
Accrued payroll and related expenses	1,055	1,083	1,317
Accrued royalties	7	-125	-1,998
Accrued income taxes payable	-3,523	-119	1,730
Other current and non-current liabilities	-141	2,803	139
Net cash provided by operating activities	25,682	19,633	47,541
INVESTING ACTIVITIES	'	'	'
Acquisitions of property and equipment	-20,821	-12,221	-4,853
Aquisition of BioHelix, net of cash acquired	-9,184	'	'
Aquisition of Andiatec	-2,250	'	'
Aquisition of intangibles	-1,680	-15,501	-16,282
Purchase of business	'	-1,000	'
Proceeds from sale of fixed assets	'	122	'
Net cash used for investing activities	-33,935	-28,600	-21,135
FINANCING ACTIVITIES	'	'	'
Proceeds from issuance of common stock, net of cancellations	7,928	4,664	59,243
Excess tax benefit from share-based compensation	2,346	1,102	12
Payments on lease obligation	-380	-329	-280
Repurchases of common stock	-2,157	-3,407	-626
Payments on line of credit	-5,000	-37,000	-30,000
Payment of note payable to state agency	'	-1,498	-211
Payment on acquisition contingency	-947	'	'
Other	'	-1,041	'
Net cash provided by (used for) financing activities	1,790	-37,509	28,138
Effect of exchange rate changes on cash	-5	'	'
Net (decrease) increase in cash and cash equivalents	-6,468	-46,476	54,544
Cash and cash equivalents, beginning of period	14,856	61,332	6,788
Cash and cash equivalents, at end of period	8,388	14,856	61,332
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION	'	'	'
Cash paid during the period for interest	1,130	1,246	2,083
Cash paid during the period for income taxes	2,211	'	350
NON-CASH INVESTING ACTIVITIES	'	'	'
Purchase of capital equipment by incurring current liabilities	172	1,086	160
Purchase of licensed technology by incurring current liabilities	'	108	14,829
Lease incentive for tenant improvements	1,658	'	'
NON-CASH FINANCING ACTIVITIES	'	'	'
Decrease of accrued payroll and related expenses upon issuance of common stock	456	917	'
Decrease of other non-current assets upon issuance of common stock	'	'	$478

Company_Operations_and_Summary

Company Operations and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Company Operations and Summary of Significant Accounting Policies	'
	Note 1. Company Operations and Summary of Significant Accounting Policies
	Quidel Corporation (the “Company”) commenced operations in 1979. The Company operates in one business segment, which develops, manufactures and markets rapid diagnostic testing solutions. These diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics and wellness screening centers. The Company markets its products in the U.S. through a network of national and regional distributors, and a direct sales force. Internationally, the Company sells and markets primarily in Japan and Europe through distributor arrangements.
	The accompanying consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with generally accepted accounting principles in the U.S.
	Consolidation—The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
	Cash and Cash Equivalents—The Company considers cash equivalents to be highly liquid investments with a maturity at the date of purchase of three months or less.
	Accounts Receivable—The Company sells its products directly to hospitals and reference laboratories in the U.S. as well as to distributors in the U.S., Europe and Japan. The Company periodically assesses the financial strength of these customers and establishes reserves for anticipated losses when necessary, which historically have not been material. The Company’s reserves primarily consist of amounts related to cash discounts and contract rebates. The balance of accounts receivable is net of reserves of $5.8 million and $5.0 million at December 31, 2013 and 2012, respectively.
	Concentration of Credit Risk—Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents and accounts receivable.
	The Company invests its cash equivalents primarily in money market funds. Cash equivalents are maintained with high quality institutions.
	The Company’s trade accounts receivable are primarily derived from sales to medical distributors, hospitals and reference laboratories in the U.S. (see Note 7). The Company performs credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary, but generally requires no collateral. Credit quality is monitored by evaluation of collection history. The Company believes that the concentration of credit risk in its trade receivables is moderated by its credit evaluation process, relatively short collection terms, the high level of credit worthiness of its customers, and letters of credit issued on the Company’s behalf. Potential credit losses are limited to the gross value of accounts receivable.
	Inventories—Inventories are stated at the lower of cost (first-in, first-out method) or market. The Company reviews the components of its inventory on a quarterly basis for excess, obsolete and impaired inventory and makes appropriate dispositions as obsolete stock is identified. Inventories consisted of the following, net of reserves of $0.6 million at December 31, 2013 and 2012 (in thousands):
		December 31,
		2013			2012
	Raw materials	$	11,938		$	5,582
	Work-in-process (materials, labor and overhead)		9,831			4,686
	Finished goods (materials, labor and overhead)		5,870			5,228
	Total inventories	$	27,639		$	15,496
	Property, Plant and Equipment—Property, plant and equipment is recorded at cost and depreciated over the estimated useful lives of the assets (three to 15 years) using the straight-line method. Amortization of leasehold improvements is computed on the straight-line method over the shorter of the lease term or the estimated useful lives of the assets. The total expense for depreciation of fixed assets and amortization of leasehold improvements was $7.9 million, $7.3 million and $6.0 million for the years ended December 31, 2013, 2012 and 2011, respectively. Maintenance and minor repairs are charged to operations as incurred.
	Property, plant and equipment consisted of the following (in thousands):
		December 31,
		2013			2012
	Equipment, furniture and fixtures	$	69,103		$	53,626
	Building and improvements		25,964			26,507
	Instruments available for lease		7,223			3,872
	Land		1,080			1,080
			103,370			85,085
	Less: accumulated depreciation and amortization		(55,313	)		(50,929	)
	Total property, plant and equipment, net	$	48,057		$	34,156
	Intangible Assets—Intangible assets are recorded at cost and amortized on a straight-line basis over their estimated useful lives, except for software development costs and indefinite-lived intangibles such as goodwill and in-process research and development. Software development costs associated with software to be sold, leased or otherwise marketed are expensed as incurred until technological feasibility has been established. After technological feasibility is established, software development costs are capitalized. The capitalized cost is amortized on a straight-line basis over the estimated product life or on the ratio of current revenues to total projected product revenues, whichever is greater. The Company capitalized $0.9 million of software costs in 2013 and expects to amortize these costs over a weighted average useful life of five years. Amortization expense related to the capitalized software costs was $0.3 million and $0.4 million for the years ended December 31, 2013 and 2012, respectively. Intangible assets consisted of the following (dollar amounts in thousands):
		Weighted-			December 31, 2013								December 31, 2012
		Average
		Useful Life			Gross			Accumulated					Gross		Accumulated
	Description	(years)			Assets			Amortization			Net		Assets		Amortization			Net
	Goodwill		Indefinite		$	84,212		$	(3,449	)	$	80,763	$	74,462	$	(3,449	)	$	71,013
	Purchased technology		8.4			51,870			(22,287	)		29,583		46,570		(16,208	)		30,362
	Customer relationships		7.5			7,250			(2,954	)		4,296		6,322		(2,007	)		4,315
	In-process research and development		Indefinite			2,260			—			2,260		1,570		—			1,570
	License agreements		5.9			34,330			(21,374	)		12,956		32,778		(12,786	)		19,992
	Patent and trademark costs		12.3			10,530			(861	)		9,669		1,390		(265	)		1,125
	Favorable lease		—			—			—			—		1,700		(1,594	)		106
	Software development costs		5			4,191			(693	)		3,498		3,262		(391	)		2,871
	Total goodwill and intangible assets				$	194,643		$	(51,618	)	$	143,025	$	168,054	$	(36,700	)	$	131,354
	The previously reported gross assets and accumulated amortization at December 31, 2012 have been restated in order to remove fully amortized assets and to conform the asset groupings with those presented at December 31, 2013.
	The Company acquired distribution rights for $0.8 million in conjunction with the March 2013 Agreement with Life Technologies Corporation (see “Collaborative Arrangement” in Note 1). The distribution rights will be amortized on a straight-line basis over the contractual term of six years. The Company acquired intangible assets in conjunction with the BioHelix Corporation (“BioHelix”) acquisition in May 2013 and the Andiatec GmbH & Co. KG (“Andiatec”) asset acquisition in August 2013, as more fully described in Note 10.
	Amortization expense was $16.6 million, $15.4 million and $11.3 million for the years ended December 31, 2013, 2012 and 2011, respectively. Included in the $16.6 million of amortization expense for 2013 is $8.0 million of amortization for licensed technology recorded in cost of sales. This amount is related to the purchase of a license pursuant to the Alere Amendment as discussed in Note 6. Amortization expense associated with this intangible asset will be recorded in cost of sales and is expected to be $8.0 million and $0.7 million for fiscal periods 2014 and 2015, respectively.
	The expected future annual amortization expense of the Company’s intangible assets is as follows (in thousands):
		Amortization
	For the years ending December 31,	Expense
	2014	$	17,705
	2015		10,324
	2016		9,485
	2017		9,183
	2018		3,613
	Thereafter		9,692
	Total	$	60,002
	The Company completed its annual evaluation for impairment of goodwill and in-process research and development as of December 31, 2013 and determined that no impairment of goodwill and indefinite lived intangible assets existed. The Company recorded a $0.5 million impairment charge of in-process research and development related to a discontinued research and development project for the year ended December 31, 2011. To value this asset, the Company considered a discounted future cash flow model. The Company determined that this asset had no future cash flows associated with it and was fully impaired. The Company classified this impairment loss as research and development expense on the Consolidated Statements of Income. A significant decline in the Company’s projected revenue or earnings growth or cash flows, a significant decline in the Company’s stock price or the stock price of comparable companies, loss of legal ownership or title to an asset, and any significant change in the Company’s strategic business objectives and utilization of assets are among many factors that could result in an impairment charge that could have a material negative impact on the Company’s operating results.
	Impairment of Long-Lived Assets—The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the total book value of an asset may not be recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and the eventual disposition are less than its carrying amount. An impairment loss is equal to the excess of the book value of an asset over its determined fair value. The Company recorded no impairment charges for the years ended December 31, 2013 and 2012. For the year ended December 31, 2011, the Company recorded $1.0 million of impairment charges on a fixed asset group related to a discontinued product. To value this asset group, the Company considered a discounted future cash flow model. The Company determined that this asset group had no future cash flows associated with it and was fully impaired. The Company classified this impairment loss as research and development expense on the Consolidated Statements of Income.
	Other current liabilities—Other current liabilities consisted of the following (in thousands):
		December 31,
		2013			2012
	Customer incentives	$	3,068		$	2,693
	Unearned grant revenue		2,029			2,156
	Income tax payable		20			955
	Customer prepayments		68			450
Accrued liability for technology licenses		180			707
Other		2,275			1,280
Total other current liabilities	$	7,640		$	8,241
Revenue Recognition—The Company records revenues primarily from product sales. These revenues are recorded net of rebates and other discounts which are estimated at the time of sale, and are largely driven by various customer program offerings, including special pricing agreements, promotions and other volume-based incentives. Revenue from product sales are recorded upon passage of title and risk of loss to the customer. Change in title to the product and recognition of revenue occurs upon delivery to the customer when sales terms are free on board (“FOB”) destination and at the time of shipment when the sales terms are FOB shipping point and there is no right of return. A portion of our product sales include revenues for diagnostic kits, which are utilized on leased instrument systems that remain our property and are capitalized on the balance sheet under property and equipment.
The Company earns income from grants for research and commercialization activities. On November 6, 2012, the Company was awarded a milestone-based grant totaling up to $8.3 million from the Bill and Melinda Gates Foundation to develop, manufacture and validate a quantitative, low-cost, nucleic acid assay for HIV drug treatment monitoring on the integrated Savanna™ MDx platform initially for use in developing countries. Upon execution of the grant agreement, the Company received $2.6 million to fund subsequent research and development activities. The Company received $2.5 million in 2013 and expects to receive milestone payments of $3.2 million in 2014. The Company will recognize grant revenue on the lessor of the amount recognized on a straight-line basis or the amount that is non-refundable through the end of the agreement, which is December 31, 2015. For the years ended December 31, 2013 and 2012, the Company recognized $2.6 million and $0.4 million, respectively, as grant revenue. The Company included $1.0 million and $2.2 million of restricted cash as a component of prepaid expense and other current assets and as a component of other current liabilities as of December 31, 2013 and 2012, respectively.
Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee. The Company also earns income from the licensing of technology.
Research and Development Costs—Research and development costs are charged to operations as incurred. In conjunction with certain third party service agreements, the Company is required to make periodic payments based on achievement of certain milestones. The costs related to these research and development services are also charged to operations as incurred.
Collaborative Arrangement— In July 2012, the Company entered into a collaborative arrangement with Life Technologies Corporation for the development of molecular assays. ASC Topic 808, Collaborative Arrangements (“ASC Topic 808”), defines a collaborative arrangement as an arrangement where the parties are active participants and have exposure to significant risks. The Company is accounting for the joint development and commercialization activities with the third-party as a joint risk sharing collaboration in accordance with ASC Topic 808. Payments from the third party, which totaled $1.4 million in 2013 and $3.0 million in 2012, are recorded as a reduction to research and development expense in the accompanying consolidated financial statements due to the nature of the activities. In connection with the executed project plan, the third party is expected to reimburse the Company an additional $0.4 million in 2014. The reimbursement represents 50% of project development costs based upon mutually agreed upon project plans for each molecular assay. In connection with the collaboration agreement, the Company also entered into a manufacturing and supply agreement with the same third party. As part of that agreement, and upon commercialization, the Company will manufacture and sell assays to the third party at cost plus 20%. Additionally, the Company will receive 40% of the gross margin for sales from the third party to the end customer. In March 2013, the Company entered into a six year instrument supply agreement (the “March 2013 Agreement”) with Life Technologies Corporation pursuant to the March 2013 Agreement the Company paid $0.8 million for distribution rights to sell Life Technologies Corporation’s QuantStudio™ DX diagnostic laboratory instrument for use in the infectious disease field, along with the assays developed under the collaborative agreement.
Product Shipment Costs—Product shipment costs are included in sales and marketing expense in the accompanying Consolidated Statements of Income. Shipping and handling costs were $2.2 million, $1.6 million and $1.6 million for the years ended December 31, 2013, 2012 and 2011, respectively.
Advertising Costs—Advertising costs are expensed as incurred. Advertising costs were $0.7 million, $0.2 million and $0.7 million for the years ended December 31, 2013, 2012 and 2011, respectively.
Deferred Rent—Rent expense is recorded on a straight-line basis over the term of the lease. The difference between rent expense and amounts paid under the lease agreement is recorded as deferred rent.
Income Taxes—Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of income tax expense.
Fair Value of Financial Instruments— The Company uses the fair value hierarchy established in ASC Topic 820, Fair Value Measurements and Disclosures, that requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed by the Company in one of the following three categories:
Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;
Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).
The carrying amounts of the Company’s financial instruments, including cash, receivables, accounts payable, and accrued liabilities approximate their fair values due to their short-term nature. The outstanding balance owed under the line of credit approximates its fair value due to the instrument’s variable interest rate feature. Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade accounts receivable. The Company establishes reserves for estimated uncollectible accounts and believes its reserves are adequate.
Product Warranty—The Company generally sells products with a limited product warranty and certain limited indemnifications. Due to product testing, the short time between product shipment and the detection and correction of product failures and a low historical rate of payments on indemnification claims, the historical activity and the related expense were not significant for the fiscal years presented.
Stock-Based Compensation—Compensation expense related to stock options granted is recognized ratably over the service vesting period for the entire option award. The total number of stock options expected to vest is adjusted by estimated forfeiture rates. The Company determined the estimated fair value of each stock option on the date of grant using the Black-Scholes option valuation model. Compensation expense for restricted stock (“stock awards”) is measured at the grant date and recognized ratably over the vesting period. The fair value of stock awards is determined based on the closing market price of the Company’s common stock on the grant date.
Computation of Earnings Per Share—Diluted net income per share is reported based on the more dilutive of the treasury stock or the two-class method. Under the two-class method, net income is allocated to common stock and participating securities. The Company’s unvested restricted stock awards and certain unvested restricted stock units meet the definition of participating securities. Basic net income per share under the two-class method is computed by dividing net income adjusted for earnings allocated to unvested stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share under the two-class method is computed by dividing net income adjusted for earnings allocated to unvested stockholders for the period by the weighted average number of common and common equivalent shares outstanding during the period. The Company excludes stock options from the calculation of diluted net income per share when the combined exercise price, unrecognized stock-based compensation and assumed tax benefits upon exercise are greater than the average market price for the Company’s common stock because their effect is anti-dilutive. Stock options totaling 0.5 million, 1.1 million and 1.8 million for the years ended December 31, 2013, 2012 and 2011, respectively were not included in the computation of diluted earnings per share as their effect was anti-dilutive. Due to the fact that the holders of participating securities are not contractually required to share in the Company’s losses, in applying the two-class method to compute basic net loss per common share, no allocation to participating securities was made for periods in which the Company incurred a net loss.
The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2013, 2012 and 2011 (in thousands, except per share amounts):
	December 31,
	2013			2012			2011
Basic net income per share:
Net income	$	7,390		$	4,993		$	7,633
Less: income allocated to participating securities		(17	)		(28	)		(68	)
Net income allocated to common stockholders	$	7,373		$	4,965		$	7,565
Weighted average common shares outstanding — basic		33,836			33,068			32,903
Net income per share — basic	$	0.22		$	0.15		$	0.23
Diluted net income per share:
Net income	$	7,390		$	4,993		$	7,633
Less: income allocated to participating securities		(16	)		(27	)		(67	)
Net income allocated to common stockholders	$	7,374		$	4,966		$	7,566
Weighted average common shares outstanding — basic		33,836			33,068			32,903
Dilutive securities		1,111			634			417
Weighted average common shares outstanding — diluted		34,947			33,702			33,320
Net income per share — diluted	$	0.21		$	0.15		$	0.23
Comprehensive Income—Comprehensive income includes unrealized gains and losses excluded from the Company’s Consolidated Statements of Income.
Facility Restructuring— The Company announced a plan to move its manufacturing operations in Santa Clara, California to Athens, Ohio. Termination benefits for those employees who chose not to relocate are accounted for in accordance with ASC Topic 712, Compensation – Nonretirement Postemployment Benefits (“ASC 712”), and are recorded when it is probable that employees will be entitled to benefits and the amounts can be reasonably estimated. Estimates of termination benefits are based on the frequency of past termination benefits and the similarity of benefits under the current plan and prior plans. Facility related costs are accounted for in accordance with ASC Topic 420, Exit or Disposal Cost Obligations (“ASC 420”), and are recorded when the liability is incurred. The Company recorded a charge of $1.8 million during the year ended December 31, 2013, which included employee termination benefits and impairment charges related to the facility lease. As of December 31, 2013 $0.8 million is included in other current liabilities in the accompanying Consolidated Balance Sheet. The facility restructuring is expected to be completed during 2014, therefore, no portion of the future estimated expenses are included in other non-current liabilities as of December 31, 2013.
Use of Estimates—The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Accounting Periods—Each of the Company’s fiscal quarters end on the Sunday closest to the end of the calendar quarter. The Company’s fiscal year end is December 29, 2013. For ease of reference, the calendar quarter end dates are used herein.
Reclassifications –The Company reclassified $0.7 million from other current liabilities to other non-current liabilities on the December 31, 2012 Consolidated Balance Sheet in order to classify interest and penalties associated with uncertain tax positions in a manner consistent with the related liability.
Recent Accounting Pronouncements—In July 2012, the FASB issued ASU No. 2012-02, Intangibles—Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment, (“ASU 2012-02”), to simplify the testing for a drop in value of intangible assets such as trademarks, patents, and distribution rights. The amended standard reduces the cost of accounting for indefinite-lived intangible assets, especially in cases where the likelihood of impairment is low. The provisions of this ASU were effective for fiscal years beginning after September 15, 2012, and the adoption did not have an impact on our consolidated financial statements.
In July 2013, the FASB issued ASU No 2013-11, Presentation of Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss or a Tax Credit Carryforward Exists, to clarify that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax benefit is disallowed. In situations where a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction or the tax law of the jurisdiction does not require, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be netted with the deferred tax asset. These amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The Company early adopted this new guidance for the year ended December 31, 2013, which did not have a material impact on the consolidated financial statements.

Line_of_Credit

Line of Credit	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Line of Credit	'
	Note 2. Line of Credit
	On August 10, 2012, the Company entered into an amended and restated $140.0 million senior secured syndicated credit facility (the “Senior Credit Facility”), which matures on August 10, 2017. As part of this amendment, the Company incurred an additional $1.0 million in deferred financing costs related to the Senior Credit Facility. The Company had previously recorded deferred financing costs of $0.6 million related to its prior credit facility. Deferred financing costs are amortized on a straight-line basis over the term of the Senior Credit Facility. As of December 31, 2013 and December 31, 2012, the Company had deferred financing costs of $1.2 million and $1.5 million, respectively, included as a portion of other non-current assets. The Senior Credit Facility bears interest at either the London Interbank Offered Rate (“LIBOR”) or the base rate, plus, in each case, an applicable margin. The base rate is equal to the highest of (i) the lender’s prime rate, (ii) the federal funds rate plus one-half of one percent and (iii) LIBOR plus one percent. The applicable margin is generally determined in accordance with a performance pricing grid based on the Company’s leverage ratio and ranges from 1.25% to 2.50% for LIBOR rate loans and from 0.25% to 1.50% for base rate loans. The agreement governing the Senior Credit Facility is subject to certain customary covenants, including among others: limitation on liens; limitation on mergers, consolidations and sales of assets; limitation on debt; limitation on dividends, stock redemptions and the redemption and/or prepayment of other debt; limitation on investments (including loans and advances) and acquisitions; limitation on transactions with affiliates; and limitation on disposition of assets. The Company is also subject to financial covenants which include a funded debt to adjusted EBITDA ratio (as defined in the Senior Credit Facility, with adjusted EBITDA generally calculated as earnings before, among other adjustments, interest, taxes, depreciation, amortization, and stock-based compensation) not to exceed 3:1 as of the end of each fiscal quarter, and an interest coverage ratio of not less than 3:1 as of the end of each fiscal quarter. The Senior Credit Facility is secured by substantially all present and future domestic assets and properties of the Company.
	As of December 31, 2013, the Company had no borrowings outstanding and had $140.0 million available under the Senior Credit Facility. The Company’s ability to borrow under the Senior Credit Facility fluctuates from time to time due to, among other factors, the Company’s borrowings under the facility and its funded debt to adjusted EBITDA ratio. As of December 31, 2012, the Company had $5.0 million outstanding under the Senior Credit Facility. As of December 31, 2013 and 2012, the Company was in compliance with all financial covenants.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Note 3. Income Taxes
	Significant components of the (benefit) provision for income taxes are as follows (in thousands):
		December 31,
		2013			2012			2011
	Current:
	Federal	$	(565	)	$	1,870		$	2,494
	State		810			377			155
	Foreign		18			—			—
	Total current provision		263			2,247			2,649
	Deferred:
	Federal		(2,584	)		811			1,422
	State		(1,635	)		(440	)		(220	)
	Total deferred (benefit) provision		(4,219	)		371			1,202
	(Benefit) provision for income taxes	$	(3,956	)	$	2,618		$	3,851
	The Company’s income before (benefit) provision for income taxes was subject to taxes in the following jurisdictions for the following periods (in thousands):
		December 31,
		2013			2012			2011
	United States	$	3,364		$	7,611		$	11,484
	Foreign		70			—			—
		$	3,434		$	7,611		$	11,484
	Significant components of the Company’s deferred tax assets as of December 31, 2013 and 2012 are shown below (in thousands).
		December 31,
		2013			2012
	Deferred tax assets:
	Net operating loss carryforwards	$	1,486		$	681
	Intangible assets		2,936			3,933
	Sale-leaseback, net		1,602			1,720
	Capitalized research and development costs		—			397
	Allowance for returns and discounts		3,155			2,800
	Stock compensation		8,192			6,298
	Tax credit carryforwards		1,351			1,520
	Other, net		4,764			3,507
	Total deferred tax assets		23,486			20,856
	Deferred tax liabilities:
	Intangible assets		(16,494	)		(13,811	)
	Fixed assets		(4,948	)		(3,772	)
	Total deferred tax liabilities		(21,442	)		(17,583	)
	Net deferred tax assets and liabilities	$	2,044		$	3,273
	The Company will continue to assess the realization of its deferred tax assets. Should the Company determine that it would not be able to realize all or part of its other components of the deferred tax asset in the future, an adjustment to the deferred tax asset would be charged to income in the period such determination were made.
	The Company recognizes excess tax benefits associated with the exercise of stock options directly to stockholders’ equity only when realized. Accordingly, deferred tax assets are not recognized for net operating loss (“NOL”) and tax credit carryforwards resulting from excess tax benefits. As of December 31, 2013 and 2012, deferred tax assets do not include $1.0 million and $1.1 million, respectively, of these excess tax benefits from employee stock option exercises that are a component of the Company’s NOL and tax credit carryforwards. Additional paid-in capital will be increased up to an additional $1.0 million if such excess tax benefits are realized.
	As of December 31, 2013, the Company had federal NOL carryforwards of approximately $2.5 million which will expire at various dates through December 31, 2019, unless previously utilized. The Company has federal research credits of $1.7 million which will begin to expire on December 31, 2031, unless previously utilized. The Company has federal alternative minimum tax credits of $0.5 million which do not expire. The Company has gross state research credits of $6.2 million which do not expire.
	Pursuant to Internal Revenue Code (“IRC”) Sections 382 and 383, the Company’s use of its NOL and research credit carryforwards may be limited as a result of cumulative changes in ownership of more than 50% over a three-year period.
	The reconciliation of income tax computed at the federal statutory rate to the (benefit) provision for income taxes from continuing operations is as follows (in thousands):
		Year ended December 31,
		2013			2012			2011
	Tax expense (benefit) at statutory tax rate	$	1,214		$	2,664		$	4,019
	State taxes (benefit), net of federal tax (benefit)		63			239			388
	Permanent differences		(76	)		26			159
	Federal and state research credits—current year		(1,046	)		(370	)		(904	)
	Federal research credits - prior year		(527	)		—			—
	Accrual for uncertain tax positions		369			(106	)		204
	Expiration of statutes for uncertain tax positions		(3,452	)		—			—
	Foreign taxes and foreign (income) losses not benefited (taxed)		(6	)		—			—
	Impact of change in federal and state tax rate on revaluing deferred tax assets		(581	)		75			39
	Other		86			90			(54	)
		$	(3,956	)	$	2,618		$	3,851
	On January 3, 2013, the American Taxpayer Relief Act of 2012 was signed into law reinstating the federal research and development credit for the 2012 and 2013 years. Accordingly, the Company recorded the benefit related to the 2012 federal research and development credit of approximately $0.5 million in the first quarter of 2013.
	The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes.
	The following table summarizes the activity related to the Company’s for unrecognized tax benefits (in thousands):
		Year ended December 31,
		2013			2012			2011
	Beginning balance	$	9,051		$	8,567		$	8,085
	Increases related to prior year tax positions		773			372			—
Increases related to current year tax positions		1,019			366			566
Expiration of the statute of limitations for the assessment of taxes		(3,078	)		(254	)		—
Other		—			—			(84	)
Ending balance	$	7,765		$	9,051		$	8,567
Included in the unrecognized tax benefits of $7.8 million at December 31, 2013 was $5.5 million of tax benefits that, if recognized, would reduce the Company’s annual effective tax rate. It is reasonably possible that the Company’s unrecognized tax benefits will decrease by $1.3 million over the next 12 months due to expiring statutes. Included in the unrecognized tax benefits of $9.1 million at December 31, 2012 was $7.2 million of tax benefits that, if recognized, would reduce the Company’s annual effective tax rate. Included in the unrecognized tax benefits of $8.6 million at December 31, 2011 was $6.9 million of tax benefits that, if recognized, would reduce the Company’s annual effective tax rate. The Company has accrued approximately $0.4 million of interest and penalties associated with uncertain tax positions as of December 31, 2013 and $0.7 million as of December 31, 2012. Interest expense, net of accrued interest reversed, in 2013, 2012, and 2011 was approximately $(0.3) million, $0.2 million, and $0.3 million, respectively.
The Company is subject to periodic audits by domestic tax authorities. During 2013, the Company was notified by the Internal Revenue Service that the Congressional Joint Committee of Taxation had completed its review and proposed no changes to the Company’s tax returns filed for the tax periods 2008 through 2010. As a result, the Company released tax reserves and related interest of approximately $3.5 million. With few exceptions, the Company’s tax years for 2000 and forward are subject to examination by the state and foreign tax authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company believes that it has appropriate support for the income tax positions taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on an assessment of many factors, including past experience and interpretations of tax law applied to the facts of each matter.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Stockholders' Equity	'
	Note 4. Stockholders’ Equity
	Preferred Stock. The Company’s certificate of incorporation, as amended, authorizes the issuance of up to five million preferred shares. The Board of Directors is authorized to fix the number of shares of any series of preferred stock and to determine the designation of such shares. However, the amended certificate of incorporation specifies the initial series and the rights of that series. No shares of preferred stock were outstanding as of December 31, 2013 or 2012.
	Restricted Stock. The Company grants time-based restricted stock awards and performance-based and time-based restricted stock units to certain officers, directors and management. Until the restrictions lapse, ownership of the affected shares of restricted stock awards or units granted to the Company’s officers is conditional upon continuous employment with the Company. During the restricted period, only holders of restricted stock awards have full voting rights with respect to their shares of restricted stock, even though the restricted stock award remains subject to transfer restrictions and generally is subject to forfeiture upon termination of employment or service. If an officer or director terminates service before the restrictions lapse, the restricted stock award is repurchased by the Company from the individual and any compensation expense previously recognized would be reversed, thereby reducing the amount of stock-based compensation expense during that period.
	For the years ended December 31, 2013, 2012 and 2011, the Company granted approximately 0.1 million, 0.1 million and 0.2 million shares, respectively, of restricted stock awards and units to officers and management, which either have a time-based four-year vesting provision or performance-based vesting provisions. A portion of the restricted stock granted in 2012 and 2011 was performance-based and vesting is tied to achievement of specific Company goals in 2014 and 2013, respectively. For purposes of measuring compensation expense, the amount of shares ultimately expected to vest is estimated at each reporting date based on management’s expectations regarding the relevant performance criteria. The recognition of compensation expense associated with performance-based restricted stock requires judgment in assessing the probability of meeting the performance goals, as well as defined criteria for assessing achievement of the performance-related goals. The grant date of the performance-based restricted stock takes place when the grant is authorized and the specific achievement goals are communicated. The communication date of the performance goals can impact the valuation and associated expense of the restricted stock.
	The performance-based restricted stock units granted in March 2011 included a three-year vesting cliff based on the achievement of a performance metric tied to earnings per share for the year ended December 31, 2013. During the fourth quarter ended December 31, 2013, the Compensation Committee of the Board of Directors amended the performance metric to include adjustments for certain items, some of which are non-recurring. This resulted in a modification of the original award and the Company recorded additional stock-based compensation expense of $1.9 million for the year ended December 31, 2013.
	During the years ended December 31, 2013, 2012 and 2011, restricted stock units were granted to certain members of the Board of Directors in lieu of cash compensation as a part of the Company’s non-employee director’s deferred compensation program. The compensation expense associated with these grants of restricted stock units was $0.4 million, $0.5 million and $0.4 million for the years ended December 31, 2013, 2012 and 2011, respectively.
	Equity Incentive Plan. The Company grants options and other stock based awards to employees and non-employee directors under its 2010 Equity Incentive Plan (the “2010 Plan”) and previously granted options under the Amended and Restated 2001 Equity Incentive Plan, the 1998 Stock Incentive Plan and the 1996 Non-Employee Directors Stock Option Plan. The 2001, 1998 and 1996 Plans were terminated at the time of adoption of the 2010 Plan, but the terminated Plans continue to govern outstanding options granted thereunder. The Company has stock options and other stock based awards outstanding, which were issued under each of these equity incentive plans to certain employees and directors. Stock options granted under the various plans have terms ranging up to ten years, have exercise prices ranging from $4.16 to $24.16 per share, and generally vest over four years. As of December 31, 2013, approximately 1.3 million shares remained available for grant under the 2010 Plan. As of December 31, 2013, the Company had $0.5 million receivable for funds related to stock option exercises and the receivable is included as a deduction from additional paid-in capital within the issuance of common stock under equity compensation plans presented in the Consolidated Statements of Stockholders’ Equity.
	Employee Deferred Bonus Compensation Program. For the year ended December 31, 2013 and 2012, certain employees of the Company were eligible to participate in the Company’s deferred bonus compensation program with respect to any payments received under the Company’s cash incentive plan. Participating employees could elect to receive 50% or 100% of the cash value of their cash bonus in the form of fully vested, restricted stock units plus an additional premium as additional restricted stock units, issued under the 2010 Plan. The premium restricted stock units are subject to a one-year vesting requirement from the date of issuance.
	The additional premium will be determined based on the length of time of the deferral period selected by the participating employee as follows: (i) if one year from the date of grant, a premium of 10% on the amount deferred, (ii) if two years from the date of grant, a premium of 20% on the amount deferred, or (iii) if four years from the date of grant, a premium of 30% on the amount deferred.
	Employee Stock Purchase Plan. Under the Company’s 1983 Employee Stock Purchase Plan (the “ESPP”), full-time employees are allowed to purchase common stock through payroll deductions (which cannot exceed 10% of the employee’s compensation) at the lower of 85% of fair market value at the beginning or end of each six-month purchase period. As of December 31, 2013, 1,039,165 shares had been sold under the Plan, leaving 210,835 shares available for future issuance.
	Share Repurchase Program. On April 23, 2013, the Company announced that the Board of Directors authorized us to repurchase up to an aggregate of $50.0 million in shares of our common stock under our stock repurchase program. Any shares of common stock repurchased under this program will no longer be deemed outstanding upon repurchase and will be returned to the pool of authorized shares. At December 31, 2013, $50.0 million remains available under this plan. The repurchase program will expire on April 22, 2015 unless extended by the Board of Directors. On December 20, 2013, the Company repurchased 37,709 shares of common stock based on the closing price of the Company’s stock on the date of the transaction from a Member of the Board of Directors, in exchange for payment for the aggregate exercise of 76,687 stock options. The stock option exercise is included in the issuance of common stock under equity compensation plans and the repurchase is included in repurchases of common stock presented in the Consolidated Statements of Stockholders’ Equity.
	Shares Reserved for Future Issuance. At December 31, 2013, approximately 5.6 million shares of common stock were reserved under the Company’s equity incentive plans, and 210,835 were reserved for purchases under the ESPP.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-Based Compensation	'
	Note 5. Stock-Based Compensation
	Compensation expense related to the Company’s share-based awards for the years ended December 31, 2013, 2012 and 2011 was $8.8 million, $6.6 million and $7.5 million, respectively, of which $4.0 million $3.8 million and $4.6 million, respectively, related to stock options and $4.0 million, $2.2 million and $2.0 million, respectively, related to restricted stock (“stock awards”). For the years ended December 31, 2013, 2012 and 2011 the Company recorded $0.8 million, $0.6 million and $0.9 million in stock-based compensation expense, respectively, associated with the deferred bonus compensation program, described in Note 4, of which $0.7 million, $0.5 million and $0.9 million, respectively, was initially recorded as a component of accrued payroll and related expenses.
	Total stock-based compensation expense, related to all of the Company’s share-based awards, was comprised as follows (in millions):
		Year ended
		December 31,
		2013			2012			2011
	Cost of sales	$	0.8		$	0.6		$	0.6
	Research and development		1.9			1.1			1
	Sales and marketing		0.9			0.6			0.5
	General and administrative		5.2			4.3			5.4
		$	8.8		$	6.6		$	7.5
	Compensation expense capitalized to inventory and compensation expense related to the Company’s ESPP were not material for the year ended December 31, 2013, 2012 and 2011.
	Stock Options
	Compensation expense related to stock options granted is recognized ratably over the service vesting period for the entire option award. For stock option awards with graded vesting, the Company ensures that the cumulative amount of compensation expense recognized at the end of any reporting period at least equals the portion of the stock option award that has vested at that date. The total number of stock option awards expected to vest is adjusted by estimated forfeiture rates. The estimated fair value of each stock option award was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for the option grants:
		Year ended
		December 31,
		2013			2012			2011
	Risk-free interest rate		0.86	%		0.83	%		1.87	%
	Expected option life (in years)		5.53			5.52			5.23
	Volatility rate		44	%		46	%		47	%
	Dividend rate		0	%		0	%		0	%
	The computation of the expected option life is based on a weighted-average calculation combining the average life of options that have already been exercised and post-vest cancellations with the estimated life of the remaining vested and unexercised options. The expected volatility is based on the historical volatility of the Company’s stock. The risk-free interest rate is based on the U.S. Treasury yield curve over the expected term of the option. The Company has never paid any cash dividends on its common stock, and does not anticipate paying any cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield of zero in the Black-Scholes option valuation model. The Company’s estimated forfeiture rate is based on its historical experience and future expectations.
	The Company’s determination of fair value is affected by the Company’s stock price as well as a number of assumptions that require judgment. The weighted-average fair value per share was $9.19, $6.51 and $5.92 for options granted during the years ended December 31, 2013, 2012 and 2011, respectively. The total intrinsic value was $8.1 million, $2.0 million and $1.2 million for options exercised during the years ended December 31, 2013, 2012 and 2011, respectively. As of December 31, 2013, total unrecognized compensation expense related to stock options was approximately $4.4 million and the related weighted-average period over which it is expected to be recognized is approximately 2.2 years. The maximum contractual term of the Company’s stock options is ten years.
	A summary of the status of stock option activity for the years ended December 31, 2011, 2012 and 2013 is as follows (in thousands, except price data and years):
					Weighted-			Weighted-
					average			average
					exercise			remaining			Aggregate
		Number			price per			contractual			intrinsic
		of Shares			share			term (in years)			value
	Outstanding at January 1, 2011		3,166		$	12.25
	Granted		617			13.61
	Exercised		(151	)		7.93
	Cancelled		(215	)		13.56
	Outstanding at December 31, 2011		3,417			12.6
	Granted		624			15.23
	Exercised		(351	)		11.85
	Cancelled		(90	)		11.94
	Outstanding at December 31, 2012		3,600			13.15
	Granted		529			22.36
	Exercised		(642	)		12.16
	Cancelled		(13	)		10.61
	Outstanding at December 31, 2013		3,474		$	14.74			6.58		$	44,127
	Vested and expected to vest at December 31, 2013		3,280		$	14.49			6.46		$	42,464
	Exercisable at December 31, 2013		2,038		$	12.76			5.4		$	29,918
	Available for future grant at December 31, 2013		1,683
	Stock Awards
	The fair value of stock awards is determined based on the closing market price of the Company’s common stock on the grant date. The Company grants both time-based and performance-based stock awards. Compensation expense for time-based stock awards is measured at the grant date and recognized ratably over the vesting period. A portion of the stock awards granted in 2012 and 2013 was performance-based and vesting is tied to achievement of specific Company goals in 2014 and 2013, respectively. For purposes of measuring compensation expense, the amount of shares ultimately expected to vest is estimated at each reporting date based on management’s expectations regarding the relevant performance criteria. The recognition of compensation expense associated with performance-based stock award requires judgment in assessing the probability of meeting the performance goals, as well as defined criteria for assessing achievement of the performance-related goals. The grant date of the performance-based stock award takes place when the grant is authorized and the specific achievement goals are communicated. The communication date of the performance goals can impact the valuation and associated expense of the stock award.
	A summary of the status of stock awards activity for the years ended December 31, 2011, 2012 and 2013 is as follows (in thousands, except price data):
					Weighted-Average
					Grant Date
		Shares			Fair Value
	Non-vested at January 1, 2011		351		$	14.02
	Granted		235			13.7
	Vested		(39	)		15.22
	Forfeited		(45	)		13.29
	Non-vested at December 31, 2011		502			13.65
	Granted		145			15.69
	Vested		(107	)		15.29
	Forfeited		(18	)		13.81
	Non-vested at December 31, 2012		522			13.87
	Granted		74			23.53
	Vested		(141	)		23.43
	Forfeited		(1	)		15.26
Non-vested at December 31, 2013		454		$	16.22
In 2013, the Company issued approximately 0.1 million restricted share units in exchange for the 2011 deferred bonus liability of $0.4 million.
The total amount of unrecognized compensation expense related to non-vested stock awards as of December 31, 2013 was approximately $1.1 million, which is expected to be recognized over a weighted-average period of approximately 1.2 years.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Note 6. Commitments and Contingencies
	Leases
	The Company leases its facilities and certain equipment. Commitments for minimum rentals under non-cancelable leases at the end of 2013 are as follows (in thousands):
	Years ending December 31,	Operating		Lease
		Leases		Obligation
	2014	$	2,363	$	1,125
	2015		1,529		1,134
	2016		2,007		1,145
	2017		1,620		1,152
	2018		1,441		1,161
	Thereafter		4,983		2,190
	Total minimum lease payments	$	13,943		7,907
	Less: amount representing interest				(2,340	)
	Present value of lease obligation				5,567
	Less: current portion				(441	)
	Long-term lease obligation			$	5,126
	Rent expense under operating leases totaled approximately $2.3 million for the year ended December 31, 2013, $2.0 million for the year ended December 31, 2012 and $1.8 million for the year ended December 31, 2011.
	In the fourth quarter of 2011, the Company entered into a new operating lease to rent approximately 11,000 square feet of additional office space in San Diego with a lease term through August 2014. In October of 2013, the Company entered into a lease for approximately 30,000 square feet of office space and the Company will move the executive and administrative functions into this facility in the second quarter of 2014. The lease expires in 2022 with options to extend the lease for two additional five-year periods. This operating lease included a lease incentive for tenant improvements of $1.7 million which has been included as a leasehold improvement in property, plant and equipment and as deferred rent in other non-current liabilities. The operating lease at the Company’s Santa Clara location has a lease term through November 2014. As a result of relocating the SPG manufacturing and research and development operations previously based in Santa Clara, California to the Company’s Athens, Ohio facility, the Company recorded a cease use charge of $0.9 million included in facility restructuring charges in the Consolidated Statement of Income (Note 1). In the fourth quarter of 2011, the Company exercised its renewal option at the Athens, Ohio location, thereby extending the lease term to 2017 with options to extend the lease for two additional five-year periods.
	During 1999, the Company completed a sale and leaseback transaction of its San Diego facility. The facility was sold for $15.0 million, of which $3.8 million was capital contributed by the Company. The sale was an all cash transaction, netting the Company approximately $7.0 million. The Company is a 25% limited partner in the partnership that acquired the facility. The transaction was deemed a financing transaction under the guidance in ASC Topic 840-40, Accounting for Sales of Real Estate. The assets sold remain on the books of the Company and will continue to be depreciated over the estimated useful life. In December 2009, the Company amended the terms of its lease agreement which had no significant impact on the Company’s financial statements. The amended terms include a new ten-year lease term through December 2019, with options to extend the lease for up to three additional five-year periods. The Company is amortizing the lease obligation over the new lease term. The amount of the monthly rental payments remain the same under the amendment. In addition, the Company has the option to purchase the general partner’s interest in the partnership in January 2015 for a fixed price. The Company has determined that the partnership is a variable interest entity (VIE). The Company is not, however, the primary beneficiary of the VIE as it does not absorb the majority of the partnership’s expected losses or receive a majority of the partnership’s residual returns. The Company made lease payments to the partnership of approximately $1.1 million for each of the three years ended December 31, 2013, 2012 and 2011.
	Purchase Commitments
	The Company has $6.2 million in firm purchase commitments with respect to planned capital expenditures as of December 31, 2013.
	Legal
	The Company is involved in various claims and litigation matters from time to time in the ordinary course of business. Management believes that all such current legal actions, in the aggregate, will not have a material adverse effect on the Company. The Company also maintains insurance, including coverage for product liability claims, in amounts which management believes are appropriate given the nature of its business. At December 31, 2013 and 2012, the Company had $0.3 million accrued as a liability for various legal matters where the Company deemed the liability probable and estimable.
	Licensing Arrangements
	On September 27, 2011, the Company entered into the Second Amendment (the “Amendment”) to Quidel/Inverness Settlement Agreement dated April 27, 2005 (the “Agreement”), as amended by an Addendum dated June 19, 2006, with Alere Inc. (formerly known as Inverness Medical Innovations, Inc.) (“Alere”).
	The Amendment, which is effective as of April 1, 2011, amends certain royalty and other provisions in the Agreement and enabled the Company to “buy-down” and “buy-out” its future royalty obligation under the Agreement for payments totaling $29.5 million. Under the Amendment, the Company made an initial cash payment of $13.8 million to Alere in September 2011 in connection with a buy-down of the Company’s royalty obligations for the period beginning July 1, 2011. In addition, the Company exercised its buy-out right for any remaining future royalty obligation by exercising the Royalty Termination Option (as defined in the Amendment) in January 2012, thereby terminating the Company’s obligation to pay future royalties under the Agreement in exchange for a fixed cash payment in the amount of $15.7 million less $1.0 million of specified third quarter 2011 royalties. This amount was paid in February 2012.
	In conjunction with Financial Accounting Standards Board Accounting Standard Update No. 2009-05, Fair Value Measurements and Disclosures (Topic 820), the Company assigned $28.8 million to the licensed technology and $0.7 million as a one-time charge to cost of sales to settle royalty claims. In determining the fair value allocation between the intangible asset licensed technology and the one-time charge to cost of sales, the Company assessed the past and estimated future revenue streams related to present and future products that use the patents that are subject to the Amendment. The effective life and related amortization of the licensed technology will be based on the higher of the percentage of usage or the straight-line method. This percentage of usage will be determined using the revenues generated from products covered by the patents that are subject to the Amendment. The terms of the Amendment provide for an estimated useful life of 3.5 years for this asset. The Company recorded $8.0 million of amortization expense in both 2013 and 2012, included as a portion of cost of sales. Prior to the buy-out, the Company recorded $4.9 million of royalty expense in 2011.
	In addition to the royalty agreement noted above, the Company has entered into various other licensing and royalty agreements, which largely require payments based on specified product sales as well as the achievement of specified milestones. The Company had royalty and license expenses relating to those agreements of approximately $1.0 million, $1.4 million and $1.9 million for the years ended December 31, 2013, 2012 and 2011, respectively.
	Research and Development Agreements
	The Company has entered into various research and development agreements which provide it with rights to develop, manufacture and market products using the intellectual property and technology of its collaborative partners. Under the terms of certain of these agreements, the Company is required to make periodic payments based on achievement of certain milestones or resource expenditures. These milestones generally include achievement of prototype assays, validation lots and clinical trials. At December 31, 2013, total current commitments due under the terms of these agreements are estimated at $2.3 million in the aggregate. The commitments will fluctuate as we agree to new phases of development under the existing arrangements.

Industry_and_Geographic_Inform

Industry and Geographic Information	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Industry and Geographic Information	'
	Note 7. Industry and Geographic Information
	The Company operates in one reportable segment. Sales to customers outside the U.S. represented 13%, 14% and 14% of total revenue for the years ended December 31, 2013, 2012 and 2011, respectively. As of December 31, 2013 and 2012, balances due from foreign customers, in U.S. dollars, were $3.2 million and $2.8 million, respectively.
	The Company had sales to individual customers in excess of 10% of total revenue, as follows:
		Year ended
		December 31,
		2013			2012			2011
	Customer:
	A		15	%		16	%		15	%
	B		17	%		18	%		17	%
			32	%		34	%		32	%
	As of December 31, 2013 and 2012, accounts receivable from individual customers with balances due in excess of 10% of total accounts receivable totaled $19.6 million and $22.4 million, respectively.
	The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory (in thousands):
		Long-lived assets as of						Total revenue year ended
		December 31,						December 31,
		2013			2012			2013			2012		2011
	United States operations
	Domestic	$	47,891		$	34,156		$	152,711		$	134,239	$	137,096
	Foreign		166			—			22,699			21,502		21,507
	Total	$	48,057		$	34,156		$	175,410		$	155,741	$	158,603
	Consolidated net product revenues by disease state are as follows (in thousands):
		Year ended December 31,
		2013(1)			2012(1)			2011(1)
	Infectious disease	$	128,079		$	110,982		$	112,227
	Women’s health		33,328			32,653			32,715
	Gastrointestinal disease		6,622			6,328			6,920
	Royalty, license fees and grant revenue		3,917			2,452			2,419
	Other		3,464			3,326			4,322
		$	175,410		$	155,741		$	158,603

Fair_Value_Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurement	'
	Note 8. Fair Value Measurement
	The following table presents the Company’s hierarchy for its assets and liabilities measured at fair value on a recurring basis as of the following periods (in thousands):
		December 31, 2013									December 31, 2012
		Level 1			Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets:
	Cash equivalents		3,056			—		—		3,056		11,000		—		—		11,000
	Total assets measured at fair value	$	3,056		$	—	$	—	$	3,056	$	11,000	$	—	$	—	$	11,000
	Liabilities:
	Senior Credit Facility		—			—		—		—		—		5,000		—		5,000
	Contingent consideration		—			—		8,808		8,808		—		—		—		—
	Total liabilities measured at fair value	$	—		$	—	$	8,808	$	8,808	$	—	$	5,000	$	—	$	5,000
	There were no transfers of assets or liabilities between Level 1, Level 2 and Level 3 categories of the fair value hierarchy during the years ended December 31, 2013 and 2012.
	The Company used Level 1 inputs to determine the fair value of its cash equivalents, which primarily consist of funds held in a money market account, and as such, the carrying value of cash equivalents approximates fair value, As of December 31, 2013 and 2012, the carrying value of cash equivalents was $3.1 million and $11.0 million, respectively. The Company used Level 2 inputs to determine the fair value of its Senior Credit Facility. There were no borrowings under the Senior Credit Facility as of December 31, 2013. As of December 31, 2012, the carrying amount of the Company’s Senior Credit Facility approximates fair value because it has a variable interest rate that reflects market changes to interest rates and changes in the Company’s leverage ratio.
	The Company reassesses the fair value of contingent consideration to be settled in cash related to acquisitions on a quarterly basis using the Monte Carlo Simulation Model for the royalty earn-out portions of the contingent liability and probability weighted models for the research and development earn-out. These are Level 3 measurements. Significant assumptions used in the measurement include probabilities of achieving the remaining milestones and the discount rates, which depend on the milestone risk profiles. Due to changes in the estimated payments and a shorter discounting period, the fair value of the contingent consideration liabilities changed, resulting in a $0.1 million loss recorded in research and development expense the consolidated statements of income during the year ended December 30, 2013.
	Changes in estimated fair value of contingent consideration liabilities from December 31, 2012 through December 30, 2013 are as follows (in thousands):
		Contingent consideration
		liability
		(Level 3 measurement)
	Balance at December 31, 2012	$	—
	Acquisition of BioHelix		9,355
	Acquisition of Andiatec		314
	Cash payment		(947	)
	Losses recorded for fair value adjustments		80
	Unrealized loss on foreign currency translation		6
	Balance at December 31, 2013	$	8,808

Employee_Benefit_Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2013
Compensation And Retirement Disclosure [Abstract]	'
Employee Benefit Plan	'
	Note 9. Employee Benefit Plan
	The Company has a defined contribution 401(k) plan (the “401(k) Plan”) covering all employees who are eligible to join the 401(k) Plan upon employment. Employee contributions are subject to a maximum limit by federal law. This Plan includes an employer match of 50% on the first 6% of pay contributed by the employee. The Company contributed approximately $0.9 million, $0.8 million and $0.8 million to the 401(k) Plan during the years ended December 31, 2013, 2012 and 2011, respectively.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Acquisitions	'
	Note 10. Acquisitions
	In October 2009, the Company entered into a product development and commercialization agreement (the “2009 Agreement”) with BioHelix under which the companies would co-develop a number of hand-held, disposable molecular assays using BioHelix’s proprietary isothermal Helicase Dependent Amplification technology. On May 6, 2013, the Company acquired BioHelix a privately-held, diagnostics company, based in Beverly, Massachusetts.
	The acquisition has been accounted for in conformity with ASC Topic 805, Business Combinations. In connection with the acquisition of BioHelix, the Company paid $9.2 million in cash, which represents cash consideration of $10.0 million adjusted for settlement of pre-existing liabilities under the 2009 Agreement and final working capital compared to an agreed upon baseline. Additionally, the Company agreed to contingent consideration ranging from $5.0 million to $13.0 million upon achievement of certain research and development milestones and revenue targets through 2018. The contingent consideration was valued at $9.4 million. A payment of $0.9 million was disbursed in the fourth quarter of 2013. As of December 31, 2013, the current portion of the contingent consideration is $1.5 million and the non-current portion of the contingent consideration is $7.0 million. The fair value of contingent consideration to be settled in cash related to the acquisition is estimated based on the Monte Carlo Simulation Model for the royalty earn-out and probability weighted models for the research and development earn-out.
	The purchase price of BioHelix is allocated to the underlying net assets acquired and liabilities assumed based on their estimated respective fair values as of May 6, 2013 with the excess purchase price allocated to goodwill. The Company’s allocation of the purchase price to the net tangible and intangible assets acquired and liabilities assumed is as follows (in thousands):
					Weighted-
					average
					amortization
					period (years)
	Acquisition consideration
	Cash consideration	$	10,000
	Settlement of pre-existing liabilities and working capital adjustment		(816	)
	Net cash consideration		9,184
	Contingent consideration		9,355
	Net consideration at closing	$	18,539
	Fair market values
	Other current and non-current assets	$	683
	Property, plant and equipment		179
	In-process research and development		690
	Purchased technology		4,340			10
	Non-compete agreement		700			5
	Contractual relationships		530			10
	Patents		8,800			12
	Goodwill		8,850
	Total assets acquired		24,772
	Accounts payable and other current liabilities		730
	Deferred tax liabilities		5,503
	Total liabilities assumed		6,233
	Purchase price allocation	$	18,539
	The goodwill of $8.9 million reflects the complementary strategic fit that the acquisition of BioHelix brought to the Company. None of the goodwill is expected to be deductible for tax purposes. In-process research and development primarily relates to the future commercialization of BioHelix’s development efforts associated with the potential commercialization of products in development at the time of the acquisition.
	The value assigned to the identifiable intangible assets was determined by discounting the estimated future cash flows associated with these assets to their present value. The revenue estimates used to value the purchased technology and patents were based on estimates of relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by BioHelix and its competitors. The rates utilized to discount the net cash flows of purchased technology and patents to their present value are based on the risks associated with the respective cash flows taking into consideration the weighted average cost of capital of the Company.
	During 2013, the Company incurred $0.3 million of transaction costs in conjunction with the BioHelix acquisition included in the Consolidated Statement of Income, which impacted both basic and diluted earnings per share by $0.01 for the year ended December 31, 2013.
	The following unaudited pro forma financial information shows the combined results of operations of the Company, including BioHelix, as if the acquisition had occurred as of the beginning of the periods presented.
		Year ended
		December 31,
	(in thousands, except per share data)	2013			2012
	Pro forma total revenues	$	176,359		$	158,071
	Pro forma net income (loss)	$	6,900		$	3,987
	Pro forma basic net earnings (loss) per share	$	0.2		$	0.12
	Pro forma diluted net earnings (loss) per share	$	0.2		$	0.12
	Total revenue included in the consolidated statements of operations	$	596
	Net loss included in the consolidated statements of operations	$	(1,505	)
	On August 26, 2013, the Company completed a business combination accomplished by acquiring the assets of Andiatec, a privately-held, diagnostics company, based in Germany. The acquisition has been accounted for in conformity with ASC Topic 805, Business Combinations. In connection with the acquisition, the Company paid $2.3 million in cash plus a hold back of $0.4 million. In addition, the Company agreed to contingent consideration of up to $0.7 million upon achievement of certain revenue targets through 2016. The purchase price has been preliminarily allocated as follows: $1.8 million in intangible assets, $0.9 million in goodwill and $0.3 million of other assets. The contingent consideration was valued at $0.3 million based on the Monte Carlo Simulation Model. During 2013, the Company incurred $0.2 million of transaction costs in conjunction with the Andiatec acquisition included in the Consolidated Statement of Income. In connection with the Andiatec acquisition, the Company agreed to pay the founder of Andiatec contingent payments of up to $4.0 million upon achievement of certain research and development milestones, subject to, continued employment. These costs are recorded as compensation expense included in research and development expense in the Consolidated Statement of Income.

Selected_Quarterly_Financial_D

Selected Quarterly Financial Data (unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Selected Quarterly Financial Data (unaudited)	'
	Note 11. Selected Quarterly Financial Data (unaudited)
			First Quarter		Second Quarter			Third Quarter			Fourth Quarter
			(in thousands, except per share data)
	2013
	Total revenues		$	61,995	$	29,706		$	33,539		$	50,170
	Cost of sales (excludes amortization of intangible assets)			19,547		13,671			15,297			18,461
	Gross profit (1)			41,010		14,524			16,695			30,126
	Total costs and expenses			44,806		36,829			39,507			50,103
	Net income (loss)			12,367		(1,755	)		(4,361	)		1,139
	Basic net earnings (loss) per share (3)			0.37		(0.05	)		(0.13	)		0.03
	Diluted net earnings (loss) per share (3)			0.36		(0.05	)		(0.13	)		0.03
	2012
	Total revenues		$	37,960	$	30,858		$	32,998		$	53,925
	Cost of sales (excludes amortization of intangible assets)			14,808		14,008			14,872			17,597
	Gross profit (2)			21,714		15,412			16,688			34,890
	Total costs and expenses			37,490		35,377			34,220			39,808
	Net income (loss)			51		(3,122	)		(676	)		8,740
	Basic and diluted net income (loss) per share (3)			0		(0.09	)		(0.02	)		0.26
	-1	Included in 2013 quarterly gross profit is amortization of intangible assets of $1.4 million, $1.5 million, $1.5 million and $1.7 million for first quarter, second quarter, third quarter and fourth quarter, respectively.
	-2	Included in 2012 quarterly gross profit is amortization of intangible assets of $1.4 million for each quarter.
	-3	Due to the computation of earnings (loss) per share, the sum of the quarterly amounts may not equal the full-year results.

Consolidated_Valuation_and_Qua

Consolidated Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2013
Valuation And Qualifying Accounts [Abstract]	'
Consolidated Valuation and Qualifying Accounts	'
	SCHEDULE II
	QUIDEL CORPORATION
	CONSOLIDATED VALUATION AND QUALIFYING ACCOUNTS
	(in thousands)
			Additions
	Description		Balance at		Charges to costs		Charges to other		Deductions (2)			Balance at end of
			beginning of		and expenses (1)		accounts					period
			period
	Year ended December 31, 2013:
	Accounts receivable allowance		$	4,955	$	15,230	$	—	$	(14,395	)	$	5,790
	Year ended December 31, 2012:
	Accounts receivable allowance		$	1,960	$	10,849	$	—	$	(7,854	)	$	4,955
	Year ended December 31, 2011:
	Accounts receivable allowance		$	1,882	$	7,909	$	—	$	(7,831	)	$	1,960
	-1	Represents charges associated primarily to accruals for early payment discounts, contract rebates and bad debt.
	-2	The deductions represent actual charges against the accrual described above.

Company_Operations_and_Summary1

Company Operations and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Consolidation	'
	Consolidation—The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents—The Company considers cash equivalents to be highly liquid investments with a maturity at the date of purchase of three months or less.
Accounts Receivable	'
	Accounts Receivable—The Company sells its products directly to hospitals and reference laboratories in the U.S. as well as to distributors in the U.S., Europe and Japan. The Company periodically assesses the financial strength of these customers and establishes reserves for anticipated losses when necessary, which historically have not been material. The Company’s reserves primarily consist of amounts related to cash discounts and contract rebates. The balance of accounts receivable is net of reserves of $5.8 million and $5.0 million at December 31, 2013 and 2012, respectively.
Concentration of Credit Risk	'
	Concentration of Credit Risk—Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents and accounts receivable.
	The Company invests its cash equivalents primarily in money market funds. Cash equivalents are maintained with high quality institutions.
	The Company’s trade accounts receivable are primarily derived from sales to medical distributors, hospitals and reference laboratories in the U.S. (see Note 7). The Company performs credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary, but generally requires no collateral. Credit quality is monitored by evaluation of collection history. The Company believes that the concentration of credit risk in its trade receivables is moderated by its credit evaluation process, relatively short collection terms, the high level of credit worthiness of its customers, and letters of credit issued on the Company’s behalf. Potential credit losses are limited to the gross value of accounts receivable.
Inventories	'
	Inventories—Inventories are stated at the lower of cost (first-in, first-out method) or market. The Company reviews the components of its inventory on a quarterly basis for excess, obsolete and impaired inventory and makes appropriate dispositions as obsolete stock is identified. Inventories consisted of the following, net of reserves of $0.6 million at December 31, 2013 and 2012 (in thousands):
		December 31,
		2013			2012
	Raw materials	$	11,938		$	5,582
	Work-in-process (materials, labor and overhead)		9,831			4,686
	Finished goods (materials, labor and overhead)		5,870			5,228
	Total inventories	$	27,639		$	15,496
Property, Plant and Equipment	'
	Property, Plant and Equipment—Property, plant and equipment is recorded at cost and depreciated over the estimated useful lives of the assets (three to 15 years) using the straight-line method. Amortization of leasehold improvements is computed on the straight-line method over the shorter of the lease term or the estimated useful lives of the assets. The total expense for depreciation of fixed assets and amortization of leasehold improvements was $7.9 million, $7.3 million and $6.0 million for the years ended December 31, 2013, 2012 and 2011, respectively. Maintenance and minor repairs are charged to operations as incurred.
	Property, plant and equipment consisted of the following (in thousands):
		December 31,
		2013			2012
	Equipment, furniture and fixtures	$	69,103		$	53,626
	Building and improvements		25,964			26,507
	Instruments available for lease		7,223			3,872
	Land		1,080			1,080
			103,370			85,085
	Less: accumulated depreciation and amortization		(55,313	)		(50,929	)
	Total property, plant and equipment, net	$	48,057		$	34,156
Intangible Assets	'
	Intangible Assets—Intangible assets are recorded at cost and amortized on a straight-line basis over their estimated useful lives, except for software development costs and indefinite-lived intangibles such as goodwill and in-process research and development. Software development costs associated with software to be sold, leased or otherwise marketed are expensed as incurred until technological feasibility has been established. After technological feasibility is established, software development costs are capitalized. The capitalized cost is amortized on a straight-line basis over the estimated product life or on the ratio of current revenues to total projected product revenues, whichever is greater. The Company capitalized $0.9 million of software costs in 2013 and expects to amortize these costs over a weighted average useful life of five years. Amortization expense related to the capitalized software costs was $0.3 million and $0.4 million for the years ended December 31, 2013 and 2012, respectively. Intangible assets consisted of the following (dollar amounts in thousands):
		Weighted-			December 31, 2013								December 31, 2012
		Average
		Useful Life			Gross			Accumulated					Gross		Accumulated
	Description	(years)			Assets			Amortization			Net		Assets		Amortization			Net
	Goodwill		Indefinite		$	84,212		$	(3,449	)	$	80,763	$	74,462	$	(3,449	)	$	71,013
	Purchased technology		8.4			51,870			(22,287	)		29,583		46,570		(16,208	)		30,362
	Customer relationships		7.5			7,250			(2,954	)		4,296		6,322		(2,007	)		4,315
	In-process research and development		Indefinite			2,260			—			2,260		1,570		—			1,570
	License agreements		5.9			34,330			(21,374	)		12,956		32,778		(12,786	)		19,992
	Patent and trademark costs		12.3			10,530			(861	)		9,669		1,390		(265	)		1,125
	Favorable lease		—			—			—			—		1,700		(1,594	)		106
	Software development costs		5			4,191			(693	)		3,498		3,262		(391	)		2,871
	Total goodwill and intangible assets				$	194,643		$	(51,618	)	$	143,025	$	168,054	$	(36,700	)	$	131,354
	The previously reported gross assets and accumulated amortization at December 31, 2012 have been restated in order to remove fully amortized assets and to conform the asset groupings with those presented at December 31, 2013.
	The Company acquired distribution rights for $0.8 million in conjunction with the March 2013 Agreement with Life Technologies Corporation (see “Collaborative Arrangement” in Note 1). The distribution rights will be amortized on a straight-line basis over the contractual term of six years. The Company acquired intangible assets in conjunction with the BioHelix Corporation (“BioHelix”) acquisition in May 2013 and the Andiatec GmbH & Co. KG (“Andiatec”) asset acquisition in August 2013, as more fully described in Note 10.
	Amortization expense was $16.6 million, $15.4 million and $11.3 million for the years ended December 31, 2013, 2012 and 2011, respectively. Included in the $16.6 million of amortization expense for 2013 is $8.0 million of amortization for licensed technology recorded in cost of sales. This amount is related to the purchase of a license pursuant to the Alere Amendment as discussed in Note 6. Amortization expense associated with this intangible asset will be recorded in cost of sales and is expected to be $8.0 million and $0.7 million for fiscal periods 2014 and 2015, respectively.
	The expected future annual amortization expense of the Company’s intangible assets is as follows (in thousands):
		Amortization
	For the years ending December 31,	Expense
	2014	$	17,705
	2015		10,324
	2016		9,485
	2017		9,183
	2018		3,613
	Thereafter		9,692
	Total	$	60,002
	The Company completed its annual evaluation for impairment of goodwill and in-process research and development as of December 31, 2013 and determined that no impairment of goodwill and indefinite lived intangible assets existed. The Company recorded a $0.5 million impairment charge of in-process research and development related to a discontinued research and development project for the year ended December 31, 2011. To value this asset, the Company considered a discounted future cash flow model. The Company determined that this asset had no future cash flows associated with it and was fully impaired. The Company classified this impairment loss as research and development expense on the Consolidated Statements of Income. A significant decline in the Company’s projected revenue or earnings growth or cash flows, a significant decline in the Company’s stock price or the stock price of comparable companies, loss of legal ownership or title to an asset, and any significant change in the Company’s strategic business objectives and utilization of assets are among many factors that could result in an impairment charge that could have a material negative impact on the Company’s operating results.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets—The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the total book value of an asset may not be recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and the eventual disposition are less than its carrying amount. An impairment loss is equal to the excess of the book value of an asset over its determined fair value. The Company recorded no impairment charges for the years ended December 31, 2013 and 2012. For the year ended December 31, 2011, the Company recorded $1.0 million of impairment charges on a fixed asset group related to a discontinued product. To value this asset group, the Company considered a discounted future cash flow model. The Company determined that this asset group had no future cash flows associated with it and was fully impaired. The Company classified this impairment loss as research and development expense on the Consolidated Statements of Income.
Other current liabilities	'
	Other current liabilities—Other current liabilities consisted of the following (in thousands):
		December 31,
		2013			2012
	Customer incentives	$	3,068		$	2,693
	Unearned grant revenue		2,029			2,156
	Income tax payable		20			955
	Customer prepayments		68			450
	Accrued liability for technology licenses		180			707
	Other		2,275			1,280
	Total other current liabilities	$	7,640		$	8,241
Revenue Recognition	'
	Revenue Recognition—The Company records revenues primarily from product sales. These revenues are recorded net of rebates and other discounts which are estimated at the time of sale, and are largely driven by various customer program offerings, including special pricing agreements, promotions and other volume-based incentives. Revenue from product sales are recorded upon passage of title and risk of loss to the customer. Change in title to the product and recognition of revenue occurs upon delivery to the customer when sales terms are free on board (“FOB”) destination and at the time of shipment when the sales terms are FOB shipping point and there is no right of return. A portion of our product sales include revenues for diagnostic kits, which are utilized on leased instrument systems that remain our property and are capitalized on the balance sheet under property and equipment.
	The Company earns income from grants for research and commercialization activities. On November 6, 2012, the Company was awarded a milestone-based grant totaling up to $8.3 million from the Bill and Melinda Gates Foundation to develop, manufacture and validate a quantitative, low-cost, nucleic acid assay for HIV drug treatment monitoring on the integrated Savanna™ MDx platform initially for use in developing countries. Upon execution of the grant agreement, the Company received $2.6 million to fund subsequent research and development activities. The Company received $2.5 million in 2013 and expects to receive milestone payments of $3.2 million in 2014. The Company will recognize grant revenue on the lessor of the amount recognized on a straight-line basis or the amount that is non-refundable through the end of the agreement, which is December 31, 2015. For the years ended December 31, 2013 and 2012, the Company recognized $2.6 million and $0.4 million, respectively, as grant revenue. The Company included $1.0 million and $2.2 million of restricted cash as a component of prepaid expense and other current assets and as a component of other current liabilities as of December 31, 2013 and 2012, respectively.
	Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee. The Company also earns income from the licensing of technology.
Research and Development Costs	'
	Research and Development Costs—Research and development costs are charged to operations as incurred. In conjunction with certain third party service agreements, the Company is required to make periodic payments based on achievement of certain milestones. The costs related to these research and development services are also charged to operations as incurred.
Collaborative Arrangement	'
	Collaborative Arrangement— In July 2012, the Company entered into a collaborative arrangement with Life Technologies Corporation for the development of molecular assays. ASC Topic 808, Collaborative Arrangements (“ASC Topic 808”), defines a collaborative arrangement as an arrangement where the parties are active participants and have exposure to significant risks. The Company is accounting for the joint development and commercialization activities with the third-party as a joint risk sharing collaboration in accordance with ASC Topic 808. Payments from the third party, which totaled $1.4 million in 2013 and $3.0 million in 2012, are recorded as a reduction to research and development expense in the accompanying consolidated financial statements due to the nature of the activities. In connection with the executed project plan, the third party is expected to reimburse the Company an additional $0.4 million in 2014. The reimbursement represents 50% of project development costs based upon mutually agreed upon project plans for each molecular assay. In connection with the collaboration agreement, the Company also entered into a manufacturing and supply agreement with the same third party. As part of that agreement, and upon commercialization, the Company will manufacture and sell assays to the third party at cost plus 20%. Additionally, the Company will receive 40% of the gross margin for sales from the third party to the end customer. In March 2013, the Company entered into a six year instrument supply agreement (the “March 2013 Agreement”) with Life Technologies Corporation pursuant to the March 2013 Agreement the Company paid $0.8 million for distribution rights to sell Life Technologies Corporation’s QuantStudio™ DX diagnostic laboratory instrument for use in the infectious disease field, along with the assays developed under the collaborative agreement.
Product Shipment Costs	'
	Product Shipment Costs—Product shipment costs are included in sales and marketing expense in the accompanying Consolidated Statements of Income. Shipping and handling costs were $2.2 million, $1.6 million and $1.6 million for the years ended December 31, 2013, 2012 and 2011, respectively.
Advertising Costs	'
	Advertising Costs—Advertising costs are expensed as incurred. Advertising costs were $0.7 million, $0.2 million and $0.7 million for the years ended December 31, 2013, 2012 and 2011, respectively.
Deferred Rent	'
	Deferred Rent—Rent expense is recorded on a straight-line basis over the term of the lease. The difference between rent expense and amounts paid under the lease agreement is recorded as deferred rent.
Income Taxes	'
	Income Taxes—Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of income tax expense.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments— The Company uses the fair value hierarchy established in ASC Topic 820, Fair Value Measurements and Disclosures, that requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed by the Company in one of the following three categories:
	Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
	Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;
	Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).
	The carrying amounts of the Company’s financial instruments, including cash, receivables, accounts payable, and accrued liabilities approximate their fair values due to their short-term nature. The outstanding balance owed under the line of credit approximates its fair value due to the instrument’s variable interest rate feature. Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade accounts receivable. The Company establishes reserves for estimated uncollectible accounts and believes its reserves are adequate.
Product Warranty	'
	Product Warranty—The Company generally sells products with a limited product warranty and certain limited indemnifications. Due to product testing, the short time between product shipment and the detection and correction of product failures and a low historical rate of payments on indemnification claims, the historical activity and the related expense were not significant for the fiscal years presented.
Stock-Based Compensation	'
	Stock-Based Compensation—Compensation expense related to stock options granted is recognized ratably over the service vesting period for the entire option award. The total number of stock options expected to vest is adjusted by estimated forfeiture rates. The Company determined the estimated fair value of each stock option on the date of grant using the Black-Scholes option valuation model. Compensation expense for restricted stock (“stock awards”) is measured at the grant date and recognized ratably over the vesting period. The fair value of stock awards is determined based on the closing market price of the Company’s common stock on the grant date.
Computation of Earnings Per Share	'
	Computation of Earnings Per Share—Diluted net income per share is reported based on the more dilutive of the treasury stock or the two-class method. Under the two-class method, net income is allocated to common stock and participating securities. The Company’s unvested restricted stock awards and certain unvested restricted stock units meet the definition of participating securities. Basic net income per share under the two-class method is computed by dividing net income adjusted for earnings allocated to unvested stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share under the two-class method is computed by dividing net income adjusted for earnings allocated to unvested stockholders for the period by the weighted average number of common and common equivalent shares outstanding during the period. The Company excludes stock options from the calculation of diluted net income per share when the combined exercise price, unrecognized stock-based compensation and assumed tax benefits upon exercise are greater than the average market price for the Company’s common stock because their effect is anti-dilutive. Stock options totaling 0.5 million, 1.1 million and 1.8 million for the years ended December 31, 2013, 2012 and 2011, respectively were not included in the computation of diluted earnings per share as their effect was anti-dilutive. Due to the fact that the holders of participating securities are not contractually required to share in the Company’s losses, in applying the two-class method to compute basic net loss per common share, no allocation to participating securities was made for periods in which the Company incurred a net loss.
	The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2013, 2012 and 2011 (in thousands, except per share amounts):
		December 31,
		2013			2012			2011
	Basic net income per share:
	Net income	$	7,390		$	4,993		$	7,633
	Less: income allocated to participating securities		(17	)		(28	)		(68	)
	Net income allocated to common stockholders	$	7,373		$	4,965		$	7,565
	Weighted average common shares outstanding — basic		33,836			33,068			32,903
	Net income per share — basic	$	0.22		$	0.15		$	0.23
	Diluted net income per share:
	Net income	$	7,390		$	4,993		$	7,633
	Less: income allocated to participating securities		(16	)		(27	)		(67	)
	Net income allocated to common stockholders	$	7,374		$	4,966		$	7,566
	Weighted average common shares outstanding — basic		33,836			33,068			32,903
	Dilutive securities		1,111			634			417
	Weighted average common shares outstanding — diluted		34,947			33,702			33,320
	Net income per share — diluted	$	0.21		$	0.15		$	0.23
Comprehensive Income	'
	Comprehensive Income—Comprehensive income includes unrealized gains and losses excluded from the Company’s Consolidated Statements of Income.
Facility Restructuring	'
	Facility Restructuring— The Company announced a plan to move its manufacturing operations in Santa Clara, California to Athens, Ohio. Termination benefits for those employees who chose not to relocate are accounted for in accordance with ASC Topic 712, Compensation – Nonretirement Postemployment Benefits (“ASC 712”), and are recorded when it is probable that employees will be entitled to benefits and the amounts can be reasonably estimated. Estimates of termination benefits are based on the frequency of past termination benefits and the similarity of benefits under the current plan and prior plans. Facility related costs are accounted for in accordance with ASC Topic 420, Exit or Disposal Cost Obligations (“ASC 420”), and are recorded when the liability is incurred. The Company recorded a charge of $1.8 million during the year ended December 31, 2013, which included employee termination benefits and impairment charges related to the facility lease. As of December 31, 2013 $0.8 million is included in other current liabilities in the accompanying Consolidated Balance Sheet. The facility restructuring is expected to be completed during 2014, therefore, no portion of the future estimated expenses are included in other non-current liabilities as of December 31, 2013.
Use of Estimates	'
	Use of Estimates—The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Accounting Periods	'
	Accounting Periods—Each of the Company’s fiscal quarters end on the Sunday closest to the end of the calendar quarter. The Company’s fiscal year end is December 29, 2013. For ease of reference, the calendar quarter end dates are used herein.
Reclassifications	'
	Reclassifications –The Company reclassified $0.7 million from other current liabilities to other non-current liabilities on the December 31, 2012 Consolidated Balance Sheet in order to classify interest and penalties associated with uncertain tax positions in a manner consistent with the related liability.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements—In July 2012, the FASB issued ASU No. 2012-02, Intangibles—Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment, (“ASU 2012-02”), to simplify the testing for a drop in value of intangible assets such as trademarks, patents, and distribution rights. The amended standard reduces the cost of accounting for indefinite-lived intangible assets, especially in cases where the likelihood of impairment is low. The provisions of this ASU were effective for fiscal years beginning after September 15, 2012, and the adoption did not have an impact on our consolidated financial statements.
	In July 2013, the FASB issued ASU No 2013-11, Presentation of Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss or a Tax Credit Carryforward Exists, to clarify that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax benefit is disallowed. In situations where a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction or the tax law of the jurisdiction does not require, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be netted with the deferred tax asset. These amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The Company early adopted this new guidance for the year ended December 31, 2013, which did not have a material impact on the consolidated financial statements.
Accounting for Sales of Real Estate	'
	During 1999, the Company completed a sale and leaseback transaction of its San Diego facility. The facility was sold for $15.0 million, of which $3.8 million was capital contributed by the Company. The sale was an all cash transaction, netting the Company approximately $7.0 million. The Company is a 25% limited partner in the partnership that acquired the facility. The transaction was deemed a financing transaction under the guidance in ASC Topic 840-40, Accounting for Sales of Real Estate. The assets sold remain on the books of the Company and will continue to be depreciated over the estimated useful life. In December 2009, the Company amended the terms of its lease agreement which had no significant impact on the Company’s financial statements. The amended terms include a new ten-year lease term through December 2019, with options to extend the lease for up to three additional five-year periods. The Company is amortizing the lease obligation over the new lease term. The amount of the monthly rental payments remain the same under the amendment. In addition, the Company has the option to purchase the general partner’s interest in the partnership in January 2015 for a fixed price. The Company has determined that the partnership is a variable interest entity (VIE). The Company is not, however, the primary beneficiary of the VIE as it does not absorb the majority of the partnership’s expected losses or receive a majority of the partnership’s residual returns. The Company made lease payments to the partnership of approximately $1.1 million for each of the three years ended December 31, 2013, 2012 and 2011.
Fair Value Measurements and Disclosures	'
	In conjunction with Financial Accounting Standards Board Accounting Standard Update No. 2009-05, Fair Value Measurements and Disclosures (Topic 820), the Company assigned $28.8 million to the licensed technology and $0.7 million as a one-time charge to cost of sales to settle royalty claims.

Company_Operations_and_Summary2

Company Operations and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Inventories	'
	Inventories consisted of the following, net of reserves of $0.6 million at December 31, 2013 and 2012 (in thousands):
		December 31,
		2013			2012
	Raw materials	$	11,938		$	5,582
	Work-in-process (materials, labor and overhead)		9,831			4,686
	Finished goods (materials, labor and overhead)		5,870			5,228
	Total inventories	$	27,639		$	15,496
Property, Plant and Equipment	'
	Property, plant and equipment consisted of the following (in thousands):
		December 31,
		2013			2012
	Equipment, furniture and fixtures	$	69,103		$	53,626
	Building and improvements		25,964			26,507
	Instruments available for lease		7,223			3,872
	Land		1,080			1,080
			103,370			85,085
	Less: accumulated depreciation and amortization		(55,313	)		(50,929	)
	Total property, plant and equipment, net	$	48,057		$	34,156
Summary of Intangible Assets	'
	Intangible assets consisted of the following (dollar amounts in thousands):
		Weighted-			December 31, 2013								December 31, 2012
		Average
		Useful Life			Gross			Accumulated					Gross		Accumulated
	Description	(years)			Assets			Amortization			Net		Assets		Amortization			Net
	Goodwill		Indefinite		$	84,212		$	(3,449	)	$	80,763	$	74,462	$	(3,449	)	$	71,013
	Purchased technology		8.4			51,870			(22,287	)		29,583		46,570		(16,208	)		30,362
	Customer relationships		7.5			7,250			(2,954	)		4,296		6,322		(2,007	)		4,315
	In-process research and development		Indefinite			2,260			—			2,260		1,570		—			1,570
	License agreements		5.9			34,330			(21,374	)		12,956		32,778		(12,786	)		19,992
	Patent and trademark costs		12.3			10,530			(861	)		9,669		1,390		(265	)		1,125
	Favorable lease		—			—			—			—		1,700		(1,594	)		106
	Software development costs		5			4,191			(693	)		3,498		3,262		(391	)		2,871
	Total goodwill and intangible assets				$	194,643		$	(51,618	)	$	143,025	$	168,054	$	(36,700	)	$	131,354
Summary of Expected Future Annual Amortization Expense	'
	The expected future annual amortization expense of the Company’s intangible assets is as follows (in thousands):
		Amortization
	For the years ending December 31,	Expense
	2014	$	17,705
	2015		10,324
	2016		9,485
	2017		9,183
	2018		3,613
	Thereafter		9,692
	Total	$	60,002
Schedule of Other Current Liabilities	'
	Other current liabilities—Other current liabilities consisted of the following (in thousands):
		December 31,
		2013			2012
	Customer incentives	$	3,068		$	2,693
	Unearned grant revenue		2,029			2,156
	Income tax payable		20			955
	Customer prepayments		68			450
	Accrued liability for technology licenses		180			707
	Other		2,275			1,280
	Total other current liabilities	$	7,640		$	8,241
Basic and Diluted EPS	'
	The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2013, 2012 and 2011 (in thousands, except per share amounts):
		December 31,
		2013			2012			2011
	Basic net income per share:
	Net income	$	7,390		$	4,993		$	7,633
	Less: income allocated to participating securities		(17	)		(28	)		(68	)
	Net income allocated to common stockholders	$	7,373		$	4,965		$	7,565
	Weighted average common shares outstanding — basic		33,836			33,068			32,903
	Net income per share — basic	$	0.22		$	0.15		$	0.23
	Diluted net income per share:
	Net income	$	7,390		$	4,993		$	7,633
	Less: income allocated to participating securities		(16	)		(27	)		(67	)
	Net income allocated to common stockholders	$	7,374		$	4,966		$	7,566
	Weighted average common shares outstanding — basic		33,836			33,068			32,903
	Dilutive securities		1,111			634			417
	Weighted average common shares outstanding — diluted		34,947			33,702			33,320
	Net income per share — diluted	$	0.21		$	0.15		$	0.23

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Components of (Benefit) Provision for Income Taxes	'
	Significant components of the (benefit) provision for income taxes are as follows (in thousands):
		December 31,
		2013			2012			2011
	Current:
	Federal	$	(565	)	$	1,870		$	2,494
	State		810			377			155
	Foreign		18			—			—
	Total current provision		263			2,247			2,649
	Deferred:
	Federal		(2,584	)		811			1,422
	State		(1,635	)		(440	)		(220	)
	Total deferred (benefit) provision		(4,219	)		371			1,202
	(Benefit) provision for income taxes	$	(3,956	)	$	2,618		$	3,851
Schedule of Income before (Benefit) Provision for Income Taxes	'
	The Company’s income before (benefit) provision for income taxes was subject to taxes in the following jurisdictions for the following periods (in thousands):
		December 31,
		2013			2012			2011
	United States	$	3,364		$	7,611		$	11,484
	Foreign		70			—			—
		$	3,434		$	7,611		$	11,484
Schedule of Deferred Tax Assets and Liabilities	'
	Significant components of the Company’s deferred tax assets as of December 31, 2013 and 2012 are shown below (in thousands).
		December 31,
		2013			2012
	Deferred tax assets:
	Net operating loss carryforwards	$	1,486		$	681
	Intangible assets		2,936			3,933
	Sale-leaseback, net		1,602			1,720
	Capitalized research and development costs		—			397
	Allowance for returns and discounts		3,155			2,800
	Stock compensation		8,192			6,298
	Tax credit carryforwards		1,351			1,520
	Other, net		4,764			3,507
	Total deferred tax assets		23,486			20,856
	Deferred tax liabilities:
	Intangible assets		(16,494	)		(13,811	)
	Fixed assets		(4,948	)		(3,772	)
	Total deferred tax liabilities		(21,442	)		(17,583	)
	Net deferred tax assets and liabilities	$	2,044		$	3,273
Reconciliation of Income Tax Computed at Federal Statutory Rate	'
	The reconciliation of income tax computed at the federal statutory rate to the (benefit) provision for income taxes from continuing operations is as follows (in thousands):
		Year ended December 31,
		2013			2012			2011
	Tax expense (benefit) at statutory tax rate	$	1,214		$	2,664		$	4,019
	State taxes (benefit), net of federal tax (benefit)		63			239			388
	Permanent differences		(76	)		26			159
	Federal and state research credits—current year		(1,046	)		(370	)		(904	)
	Federal research credits - prior year		(527	)		—			—
	Accrual for uncertain tax positions		369			(106	)		204
	Expiration of statutes for uncertain tax positions		(3,452	)		—			—
	Foreign taxes and foreign (income) losses not benefited (taxed)		(6	)		—			—
	Impact of change in federal and state tax rate on revaluing deferred tax assets		(581	)		75			39
	Other		86			90			(54	)
		$	(3,956	)	$	2,618		$	3,851
Summary of Unrecognized Tax Benefits	'
	The following table summarizes the activity related to the Company’s for unrecognized tax benefits (in thousands):
		Year ended December 31,
		2013			2012			2011
	Beginning balance	$	9,051		$	8,567		$	8,085
	Increases related to prior year tax positions		773			372			—
	Increases related to current year tax positions		1,019			366			566
	Expiration of the statute of limitations for the assessment of taxes		(3,078	)		(254	)		—
	Other		—			—			(84	)
	Ending balance	$	7,765		$	9,051		$	8,567

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Compensation Expense Related to Stock-Based Compensation Plans	'
	Total stock-based compensation expense, related to all of the Company’s share-based awards, was comprised as follows (in millions):
		Year ended
		December 31,
		2013			2012			2011
	Cost of sales	$	0.8		$	0.6		$	0.6
	Research and development		1.9			1.1			1
	Sales and marketing		0.9			0.6			0.5
	General and administrative		5.2			4.3			5.4
		$	8.8		$	6.6		$	7.5
Estimated Fair Value of Each Stock Option Award	'
	The estimated fair value of each stock option award was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for the option grants:
		Year ended
		December 31,
		2013			2012			2011
	Risk-free interest rate		0.86	%		0.83	%		1.87	%
	Expected option life (in years)		5.53			5.52			5.23
	Volatility rate		44	%		46	%		47	%
	Dividend rate		0	%		0	%		0	%
Summary of Status of Stock Option Activity	'
	A summary of the status of stock option activity for the years ended December 31, 2011, 2012 and 2013 is as follows (in thousands, except price data and years):
					Weighted-			Weighted-
					average			average
					exercise			remaining			Aggregate
		Number			price per			contractual			intrinsic
		of Shares			share			term (in years)			value
	Outstanding at January 1, 2011		3,166		$	12.25
	Granted		617			13.61
	Exercised		(151	)		7.93
	Cancelled		(215	)		13.56
	Outstanding at December 31, 2011		3,417			12.6
	Granted		624			15.23
	Exercised		(351	)		11.85
	Cancelled		(90	)		11.94
	Outstanding at December 31, 2012		3,600			13.15
	Granted		529			22.36
	Exercised		(642	)		12.16
	Cancelled		(13	)		10.61
	Outstanding at December 31, 2013		3,474		$	14.74			6.58		$	44,127
	Vested and expected to vest at December 31, 2013		3,280		$	14.49			6.46		$	42,464
	Exercisable at December 31, 2013		2,038		$	12.76			5.4		$	29,918
	Available for future grant at December 31, 2013		1,683
Summary of Status of Stock Awards Activity	'
	A summary of the status of stock awards activity for the years ended December 31, 2011, 2012 and 2013 is as follows (in thousands, except price data):
					Weighted-Average
					Grant Date
		Shares			Fair Value
	Non-vested at January 1, 2011		351		$	14.02
	Granted		235			13.7
	Vested		(39	)		15.22
	Forfeited		(45	)		13.29
	Non-vested at December 31, 2011		502			13.65
	Granted		145			15.69
	Vested		(107	)		15.29
	Forfeited		(18	)		13.81
	Non-vested at December 31, 2012		522			13.87
	Granted		74			23.53
	Vested		(141	)		23.43
	Forfeited		(1	)		15.26
	Non-vested at December 31, 2013		454		$	16.22

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments for Minimum Rentals under Non-cancelable Leases	'
	The Company leases its facilities and certain equipment. Commitments for minimum rentals under non-cancelable leases at the end of 2013 are as follows (in thousands):
	Years ending December 31,	Operating		Lease
		Leases		Obligation
	2014	$	2,363	$	1,125
	2015		1,529		1,134
	2016		2,007		1,145
	2017		1,620		1,152
	2018		1,441		1,161
	Thereafter		4,983		2,190
	Total minimum lease payments	$	13,943		7,907
	Less: amount representing interest				(2,340	)
	Present value of lease obligation				5,567
	Less: current portion				(441	)
	Long-term lease obligation			$	5,126

Industry_and_Geographic_Inform1

Industry and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Sales to Individual Customers in Excess of 10% of Total Revenue	'
	The Company had sales to individual customers in excess of 10% of total revenue, as follows:
		Year ended
		December 31,
		2013			2012			2011
	Customer:
	A		15	%		16	%		15	%
	B		17	%		18	%		17	%
			32	%		34	%		32	%
Long-Lived Assets (Excluding Intangible Assets) and Total Net Revenue	'
	The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory (in thousands):
		Long-lived assets as of						Total revenue year ended
		December 31,						December 31,
		2013			2012			2013			2012		2011
	United States operations
	Domestic	$	47,891		$	34,156		$	152,711		$	134,239	$	137,096
	Foreign		166			—			22,699			21,502		21,507
	Total	$	48,057		$	34,156		$	175,410		$	155,741	$	158,603
Consolidated Net Product Revenues by Disease State	'
	Consolidated net product revenues by disease state are as follows (in thousands):
		Year ended December 31,
		2013(1)			2012(1)			2011(1)
	Infectious disease	$	128,079		$	110,982		$	112,227
	Women’s health		33,328			32,653			32,715
	Gastrointestinal disease		6,622			6,328			6,920
	Royalty, license fees and grant revenue		3,917			2,452			2,419
	Other		3,464			3,326			4,322
		$	175,410		$	155,741		$	158,603

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Assets and Liabilities Measured at Fair Value on Recurring Basis	'
	The following table presents the Company’s hierarchy for its assets and liabilities measured at fair value on a recurring basis as of the following periods (in thousands):
		December 31, 2013									December 31, 2012
		Level 1			Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets:
	Cash equivalents		3,056			—		—		3,056		11,000		—		—		11,000
	Total assets measured at fair value	$	3,056		$	—	$	—	$	3,056	$	11,000	$	—	$	—	$	11,000
	Liabilities:
	Senior Credit Facility		—			—		—		—		—		5,000		—		5,000
	Contingent consideration		—			—		8,808		8,808		—		—		—		—
	Total liabilities measured at fair value	$	—		$	—	$	8,808	$	8,808	$	—	$	5,000	$	—	$	5,000
Changes in Estimated Fair Value of Contingent Consideration Liabilities	'
	Changes in estimated fair value of contingent consideration liabilities from December 31, 2012 through December 30, 2013 are as follows (in thousands):
		Contingent consideration
		liability
		(Level 3 measurement)
	Balance at December 31, 2012	$	—
	Acquisition of BioHelix		9,355
	Acquisition of Andiatec		314
	Cash payment		(947	)
	Losses recorded for fair value adjustments		80
	Unrealized loss on foreign currency translation		6
	Balance at December 31, 2013	$	8,808

Acquisitions_Tables

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Allocation of Purchase Price to Net Tangible and Intangible Assets Acquired and Liabilities	'
	The Company’s allocation of the purchase price to the net tangible and intangible assets acquired and liabilities assumed is as follows (in thousands):
					Weighted-
					average
					amortization
					period (years)
	Acquisition consideration
	Cash consideration	$	10,000
	Settlement of pre-existing liabilities and working capital adjustment		(816	)
	Net cash consideration		9,184
	Contingent consideration		9,355
	Net consideration at closing	$	18,539
	Fair market values
	Other current and non-current assets	$	683
	Property, plant and equipment		179
	In-process research and development		690
	Purchased technology		4,340			10
	Non-compete agreement		700			5
	Contractual relationships		530			10
	Patents		8,800			12
	Goodwill		8,850
	Total assets acquired		24,772
	Accounts payable and other current liabilities		730
	Deferred tax liabilities		5,503
	Total liabilities assumed		6,233
	Purchase price allocation	$	18,539
Schedule of Pro Forma Financial Information	'
	The following unaudited pro forma financial information shows the combined results of operations of the Company, including BioHelix, as if the acquisition had occurred as of the beginning of the periods presented.
		Year ended
		December 31,
	(in thousands, except per share data)	2013			2012
	Pro forma total revenues	$	176,359		$	158,071
	Pro forma net income (loss)	$	6,900		$	3,987
	Pro forma basic net earnings (loss) per share	$	0.2		$	0.12
	Pro forma diluted net earnings (loss) per share	$	0.2		$	0.12
	Total revenue included in the consolidated statements of operations	$	596
	Net loss included in the consolidated statements of operations	$	(1,505	)

Selected_Quarterly_Financial_D1

Selected Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Data	'
			First Quarter		Second Quarter			Third Quarter			Fourth Quarter
			(in thousands, except per share data)
	2013
	Total revenues		$	61,995	$	29,706		$	33,539		$	50,170
	Cost of sales (excludes amortization of intangible assets)			19,547		13,671			15,297			18,461
	Gross profit (1)			41,010		14,524			16,695			30,126
	Total costs and expenses			44,806		36,829			39,507			50,103
	Net income (loss)			12,367		(1,755	)		(4,361	)		1,139
	Basic net earnings (loss) per share (3)			0.37		(0.05	)		(0.13	)		0.03
	Diluted net earnings (loss) per share (3)			0.36		(0.05	)		(0.13	)		0.03
	2012
	Total revenues		$	37,960	$	30,858		$	32,998		$	53,925
	Cost of sales (excludes amortization of intangible assets)			14,808		14,008			14,872			17,597
	Gross profit (2)			21,714		15,412			16,688			34,890
	Total costs and expenses			37,490		35,377			34,220			39,808
	Net income (loss)			51		(3,122	)		(676	)		8,740
	Basic and diluted net income (loss) per share (3)			0		(0.09	)		(0.02	)		0.26
	-1	Included in 2013 quarterly gross profit is amortization of intangible assets of $1.4 million, $1.5 million, $1.5 million and $1.7 million for first quarter, second quarter, third quarter and fourth quarter, respectively.
	-2	Included in 2012 quarterly gross profit is amortization of intangible assets of $1.4 million for each quarter.
	-3	Due to the computation of earnings (loss) per share, the sum of the quarterly amounts may not equal the full-year results.

Company_Operations_and_Summary3

Company Operations and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

Share data in Millions, unless otherwise specified

Nov. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2013

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Segment

Other Current Liabilities [Member]

Other Noncurrent Liabilities [Member]

Software development costs [Member]

Capitalized Software Costs [Member]

Capitalized Software Costs [Member]

Distribution rights [Member]

Distribution rights [Member]

License agreements [Member]

License agreements [Member]

License agreements [Member]

Minimum [Member]

Maximum [Member]

Cost of sales [Member]

Acquired Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of business segment

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and cash equivalents maximum maturity period

'

'3 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Account receivable, reserves

'

$5,800,000

$5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Net of reserves, inventories

'

600,000

600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated useful lives of the assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'15 years

Depreciation and Amortization

'

7,900,000

7,300,000

6,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Expected life for amortization of distribution rights

'

'3 years 6 months

'

'

'

'

'5 years

'

'

'6 years

'

'5 years 10 months 24 days

'

'

'

'

Acquisition of distribution rights

'

'

'

'

'

'

900,000

'

'

800,000

'

'

'

'

'

'

Amortization expense

'

16,600,000

15,400,000

11,300,000

'

'

'

300,000

400,000

'

'

8,000,000

8,000,000

8,000,000

'

'

Amortization of intangible assets expected to be recognized during the next fiscal year

'

17,705,000

'

'

'

'

'

'

'

'

'

'

'

8,000,000

'

'

Amortization of intangible assets expected to be recognized during the second fiscal year

'

10,324,000

'

'

'

'

'

'

'

'

'

'

'

700,000

'

'

Impairment of Long-Lived Assets

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

Impairment charges on fixed assets

'

0

0

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Company's milestone-based grant

8,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fund received for research and development activities

2,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Company's expectation to receive milestone payment in 2014

'

'

3,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Milestone payments received

'

2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Company's grant revenue

'

2,600,000

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted cash as a component of prepaid expenses

'

1,000,000

2,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Reimbursement related to research and development expense

'

1,400,000

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected additional reimbursement related to research and development expense

'

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reimbursement percentage upon project development cost

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage cost plus sale assays to third party

'

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest in gross margin for sales from third party to end customer

'

40.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period of instrument supply agreement with Life Technologies Corporation

'

'

'

'

'

'

'

'

'

'

'6 years

'

'

'

'

'

Acquisition of distribution rights

'

'

'

'

'

'

'

'

'

'

800,000

'

'

'

'

'

Product shipment costs

'

2,200,000

1,600,000

1,600,000

'

'

'

'

'

'

'

'

'

'

'

'

Advertising cost expensed

'

700,000

200,000

700,000

'

'

'

'

'

'

'

'

'

'

'

'

Stock Options excluded from calculation of diluted (loss) earnings per share ("EPS")

'

0.5

1.1

1.8

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring Charges

'

1,825,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other current liabilities

'

800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Future estimated expenses

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reclassified from other current liabilities to other non-current liabilities

'

'

'

'

($700,000)

$700,000

'

'

'

'

'

'

'

'

'

'

Company_Operations_and_Summary4

Company Operations and Summary of Significant Accounting Policies - Summary of Inventories (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$11,938	$5,582
Work-in-process (materials, labor and overhead)	9,831	4,686
Finished goods (materials, labor and overhead)	5,870	5,228
Total inventories	$27,639	$15,496

Company_Operations_and_Summary5

Company Operations and Summary of Significant Accounting Policies - Property, Plant and equipment (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	$103,370	$85,085
Less: accumulated depreciation and amortization	-55,313	-50,929
Total property, plant and equipment, net	48,057	34,156
Equipment, furniture and fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	69,103	53,626
Building and building improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	25,964	26,507
Instruments available for lease [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	7,223	3,872
Land [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	$1,080	$1,080

Company_Operations_and_Summary6

Company Operations and Summary of Significant Accounting Policies - Summary of Intangible Assets (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Goodwill And Intangible Assets [Line Items]	'	'
Gross intangible asset including Goodwill	$194,643	$168,054
Weighted-Average Useful Life (years)	'3 years 6 months	'
Accumulated Amortization	-51,618	-36,700
Net intangible asset including Goodwill	143,025	131,354
Net	60,002	'
Goodwill Gross	84,212	74,462
Accumulated Amortization on Goodwill	-3,449	-3,449
Goodwill Net	80,763	71,013
In-process research and development [Member]	'	'
Goodwill And Intangible Assets [Line Items]	'	'
Gross Assets	2,260	1,570
Accumulated Amortization	'	'
Net	2,260	1,570
Purchased technology [Member]	'	'
Goodwill And Intangible Assets [Line Items]	'	'
Weighted-Average Useful Life (years)	'8 years 4 months 24 days	'
Gross Assets	51,870	46,570
Accumulated Amortization	-22,287	-16,208
Net	29,583	30,362
Customer relationships [Member]	'	'
Goodwill And Intangible Assets [Line Items]	'	'
Weighted-Average Useful Life (years)	'7 years 6 months	'
Gross Assets	7,250	6,322
Accumulated Amortization	-2,954	-2,007
Net	4,296	4,315
License agreements [Member]	'	'
Goodwill And Intangible Assets [Line Items]	'	'
Weighted-Average Useful Life (years)	'5 years 10 months 24 days	'
Gross Assets	34,330	32,778
Accumulated Amortization	-21,374	-12,786
Net	12,956	19,992
Patent and trademark costs [Member]	'	'
Goodwill And Intangible Assets [Line Items]	'	'
Weighted-Average Useful Life (years)	'12 years 3 months 18 days	'
Gross Assets	10,530	1,390
Accumulated Amortization	-861	-265
Net	9,669	1,125
Favorable lease [Member]	'	'
Goodwill And Intangible Assets [Line Items]	'	'
Weighted-Average Useful Life (years)	'0 years	'
Gross Assets	'	1,700
Accumulated Amortization	'	-1,594
Net	'	106
Software development costs [Member]	'	'
Goodwill And Intangible Assets [Line Items]	'	'
Weighted-Average Useful Life (years)	'5 years	'
Gross Assets	4,191	3,262
Accumulated Amortization	-693	-391
Net	$3,498	$2,871

Company_Operations_and_Summary7

Company Operations and Summary of Significant Accounting Policies - Summary of Expected Future Annual Amortization Expense (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite Lived Intangible Assets Future Amortization Expense [Abstract]	'
2014	$17,705
2015	10,324
2016	9,485
2017	9,183
2018	3,613
Thereafter	9,692
Net	$60,002

Company_Operations_and_Summary8

Company Operations and Summary of Significant Accounting Policies - Other Current Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Other Liabilities Disclosure [Abstract]	'	'
Customer incentives	$3,068	$2,693
Unearned grant revenue	2,029	2,156
Income tax payable	20	955
Customer prepayments	68	450
Accrued liability for technology licenses	180	707
Other	2,275	1,280
Total other current liabilities	$7,640	$8,241

Company_Operations_and_Summary9

Company Operations and Summary of Significant Accounting Policies - Basic and Diluted EPS (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Basic net income per share:	'	'	'	'	'	'	'	'	'	'	'
Net income	$1,139	($4,361)	($1,755)	$12,367	$8,740	($676)	($3,122)	$51	$7,390	$4,993	$7,633
Less: income allocated to participating securities	'	'	'	'	'	'	'	'	-17	-28	-68
Net income allocated to common stockholders	'	'	'	'	'	'	'	'	7,373	4,965	7,565
Weighted average common shares outstanding - basic	'	'	'	'	'	'	'	'	33,836	33,068	32,903
Net income per share - basic	$0.03	($0.13)	($0.05)	$0.37	'	'	'	'	$0.22	$0.15	$0.23
Diluted net income per share:	'	'	'	'	'	'	'	'	'	'	'
Net income	1,139	-4,361	-1,755	12,367	8,740	-676	-3,122	51	7,390	4,993	7,633
Less: income allocated to participating securities	'	'	'	'	'	'	'	'	-16	-27	-67
Net income allocated to common stockholders	'	'	'	'	'	'	'	'	$7,374	$4,966	$7,566
Weighted average common shares outstanding - basic	'	'	'	'	'	'	'	'	33,836	33,068	32,903
Dilutive securities	'	'	'	'	'	'	'	'	1,111	634	417
Weighted average common shares outstanding - diluted	'	'	'	'	'	'	'	'	34,947	33,702	33,320
Net income per share - diluted	$0.03	($0.13)	($0.05)	$0.36	'	'	'	'	$0.21	$0.15	$0.23

Line_of_Credit_Additional_Info

Line of Credit - Additional Information (Detail) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Aug. 31, 2012

Dec. 31, 2013

Aug. 10, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Other non-current assets [Member]

Other non-current assets [Member]

Senior Credit Facility [Member]

Senior Credit Facility [Member]

Senior Credit Facility [Member]

Senior Credit Facility [Member]

Senior Credit Facility [Member]

Senior Credit Facility [Member]

Senior Credit Facility [Member]

Senior Credit Facility [Member]

Senior Credit Facility [Member]

Senior Credit Facility [Member]

Scenario, previously reported [Member]

Federal funds rate [Member]

LIBOR [Member]

LIBOR [Member]

LIBOR [Member]

Base rate loans [Member]

Base rate loans [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Line of Credit Facility [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Senior Credit Facility

'

'

'

'

'

'

$140

'

'

'

'

'

'

'

Deferred financing costs

'

'

1.2

1.5

'

1

'

0.6

'

'

'

'

'

'

Senior Credit Facility, maturity date

'

'

'

'

10-Aug-17

'

'

'

'

'

'

'

'

'

Base rate

'

'

'

'

'

'

'

'

0.50%

1.00%

'

'

'

'

Senior Credit Facility, applicable margin

'

'

'

'

'

'

'

'

'

'

2.50%

1.25%

1.50%

0.25%

Line of credit facility restrictive covenants

'

'

'

'

'

'The agreement governing the Senior Credit Facility is subject to certain customary covenants, including among others limitation on liens; limitation on mergers, consolidations and sales of assets; limitation on debt; limitation on dividends, stock redemptions and the redemption and/or prepayment of other debt; limitation on investments (including loans and advances) and acquisitions; limitation on transactions with affiliates; and limitation on disposition of assets.

'

'

'

'

'

'

'

'

Senior Credit Facility, adjusted EBITDA ratio

'

'

'

'

'

3

'

'

'

'

'

'

'

'

Senior Credit Facility, Interest coverage ratio

'

'

'

'

'

3

'

'

'

'

'

'

'

'

Amount available under the Senior Credit Facility

140

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount outstanding under the Senior Credit Facility

$0

$5

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit facility covenant compliance

'The Company was in compliance with all financial covenants

'

'

'

'

'

'

'

'

'

'

'

'

'

Income_Taxes_Components_of_Ben

Income Taxes - Components of (Benefit) Provision for Income Taxes (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current:	'	'	'
Federal	($565)	$1,870	$2,494
State	810	377	155
Foreign	18	'	'
Total current provision	263	2,247	2,649
Deferred:	'	'	'
Federal	-2,584	811	1,422
State	-1,635	-440	-220
Total deferred (benefit) provision	-4,219	371	1,202
(Benefit) provision for income taxes	($3,956)	$2,618	$3,851

Income_Taxes_Schedule_of_Incom

Income Taxes - Schedule of Income before (Benefit) Provision for Income Taxes (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
United States	$3,364	$7,611	$11,484
Foreign	70	'	'
Income before (benefit) provision for income taxes	$3,434	$7,611	$11,484

Income_Taxes_Schedule_of_Defer

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred tax assets:	'	'
Net operating loss carryforwards	$1,486	$681
Intangible assets	2,936	3,933
Sale-leaseback, net	1,602	1,720
Capitalized research and development costs	'	397
Allowance for returns and discounts	3,155	2,800
Stock compensation	8,192	6,298
Tax credit carryforwards	1,351	1,520
Other, net	4,764	3,507
Total deferred tax assets	23,486	20,856
Deferred tax liabilities:	'	'
Intangible assets	-16,494	-13,811
Fixed assets	-4,948	-3,772
Total deferred tax liabilities	-21,442	-17,583
Net deferred tax assets and liabilities	$2,044	$3,273

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended				12 Months Ended		3 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2013	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2013
					Federal research credits [Member]	Gross State Research Credits [Member]	Federal [Member]	Scenario, Forecast [Member]
Income Taxes Disclosure [Line Items]	'	'	'	'	'	'	'	'
Deferred tax benefits	$1,000,000	$1,100,000	'	'	'	'	'	'
Impact of excess tax benefit in additional paid-in capital	2,346,000	1,102,000	12,000	'	'	'	'	1,000,000
Federal Net Operating Loss carryforwards	2,500,000	'	'	'	'	'	'	'
Federal research credits	'	'	'	'	1,700,000	'	'	'
Federal research credits, expiration date	'	'	'	'	31-Dec-31	'	'	'
Federal alternative minimum tax credit	500,000	'	'	'	'	'	'	'
Gross research credits	1,046,000	370,000	904,000	'	'	6,200,000	500,000	'
Cumulative changes in ownership percentage	50.00%	'	'	'	'	'	'	'
Cumulative changes in ownership period	'3 years	'	'	'	'	'	'	'
Realized upon settlement	50.00%	'	'	'	'	'	'	'
Unrecognized tax benefits	7,765,000	9,051,000	8,567,000	8,085,000	'	'	'	'
Unrecognized tax benefits decrease from current period	1,300,000	'	'	'	'	'	'	'
Unrecognized tax benefits that would impact effective tax rate	5,500,000	7,200,000	6,900,000	'	'	'	'	'
Accrued interest and penalties associated with uncertain tax positions	400,000	700,000	'	'	'	'	'	'
Interest expense, net of accrued interest reversed	-300,000	200,000	300,000	'	'	'	'	'
Income tax reserves and related interest	$3,500,000	'	'	'	'	'	'	'

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of Income Tax Computed at Federal Statutory Rate (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Tax expense (benefit) at statutory tax rate	$1,214	$2,664	$4,019
State taxes (benefit), net of federal tax (benefit)	63	239	388
Permanent differences	-76	26	159
Federal and state research credits-current year	-1,046	-370	-904
Federal research credits - prior year	-527	'	'
Accrual for uncertain tax positions	369	-106	204
Expiration of statutes for uncertain tax positions	-3,452	'	'
Foreign taxes and foreign (income) losses not benefited (taxed)	-6	'	'
Impact of change in federal and state tax rate on revaluing deferred tax assets	-581	75	39
Other	86	90	-54
(Benefit) provision for income taxes	($3,956)	$2,618	$3,851

Income_Taxes_Summary_of_Unreco

Income Taxes - Summary of Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Unrecognized tax benefits, beginning balance	$9,051	$8,567	$8,085
Increases related to prior year tax positions	773	372	'
Increases related to current year tax positions	1,019	366	566
Expiration of the statute of limitations for the assessment of taxes	-3,078	-254	'
Other	'	'	-84
Unrecognized tax benefits, ending balance	$7,765	$9,051	$8,567

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)

0 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

Apr. 23, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 20, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Restricted stock [Member]

Restricted stock [Member]

Restricted stock [Member]

2010 Plan [Member]

Non-employee director [Member]

Non-employee director [Member]

Non-employee director [Member]

Member of Board of Directors [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

2010 Plan [Member]

2010 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

Preferred stock, shares outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted stock granted

'

74,000

145,000

235,000

'

100,000

100,000

200,000

'

400,000

500,000

400,000

'

'

'

'

'

Performance-based vesting period

'

'

'

'

'

'4 years

'4 years

'4 years

'4 years

'

'

'

'

'

'

'

'

Additional stock-based compensation expense

'

$1,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options outstanding under equity incentive plans

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

Exercise price of stock

'

$14.74

$13.15

$12.60

$12.25

'

'

'

'

'

'

'

'

'

$4.16

'

$24.16

Grant shares under 2010 Plan

'

1,683,000

'

'

'

'

'

'

1,300,000

'

'

'

'

'

'

'

'

Receivable for stock option exercises

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of deferred 2011 cash bonus

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

100.00%

'

Percentage of premium on amount deferred (Condition 1)

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of premium on amount deferred (Condition 2)

'

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of premium on amount deferred (Condition 3)

'

30.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred period of grants (Condition 1)

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred period of grants (Condition 2)

'

'2 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred period of grants (Condition 3)

'

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum percentage of common stock under payroll deductions

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of payroll deductions

'

85.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock sold under the plan

'

1,039,165

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Capital shares reserved for future issuance

'

210,835

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments for repurchase of common stock

50,000,000

2,157,000

3,407,000

626,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Expiration of repurchase program

'

22-Apr-15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock repurchase program remaining available amount

'

$50,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repurchase of available shares under share repurchase program

'

'

'

'

'

'

'

'

'

'

'

'

37,709

'

'

'

'

Exercise of stock options

'

642,000

351,000

151,000

'

'

'

'

'

'

'

'

76,687

'

'

'

'

Common stock reserve under equity incentive plans

'

'

'

'

'

'

'

'

5,600,000

'

'

'

'

'

'

'

'

Shares reserved for purchase under ESPP

'

210,835

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	12 Months Ended
Share data in Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based compensation expense recognized	$8,800,000	$6,600,000	$7,500,000
Cash dividends	0	'	'
Expected dividend yield	0.00%	0.00%	0.00%
Weighted-average grant date fair value of stock options granted	$9.19	$6.51	$5.92
Total intrinsic value for options exercised	8,100,000	2,000,000	1,200,000
Total unrecognized compensation expense related to non-vested stock options	4,400,000	'	'
Expected weighted-average period of recognition for unrecognized compensation expense	'2 years 2 months 12 days	'	'
Maximum contractual term	'10 years	'	'
Deferred bonus liability amount	400,000	'	'
Deferred bonus compensation program [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based compensation expense recognized	800,000	600,000	900,000
Recorded as a component of accrued payroll and related expenses	700,000	500,000	900,000
Restricted stock [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based compensation expense recognized	4,000,000	2,200,000	2,000,000
Expected weighted-average period of recognition for unrecognized compensation expense	'1 year 2 months 12 days	'	'
Number of restricted share units issued	0.1	'	'
Total unrecognized compensation expense related to non-vested stock awards	1,100,000	'	'
Stock options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based compensation expense recognized	$4,000,000	$3,800,000	$4,600,000

StockBased_Compensation_Compen

Stock-Based Compensation - Compensation Expense Related to Stock-Based Compensation Plans (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation expense	$8.80	$6.60	$7.50
Cost of sales [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation expense	0.8	0.6	0.6
Research and development [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation expense	1.9	1.1	1
Sales and marketing [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation expense	0.9	0.6	0.5
General and administrative [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation expense	$5.20	$4.30	$5.40

StockBased_Compensation_Estima

Stock-Based Compensation - Estimated Fair Value of Each Stock Option Award (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Equity [Abstract]	'	'	'
Risk-free interest rate	0.86%	0.83%	1.87%
Expected option life (in years)	'5 years 6 months 11 days	'5 years 6 months 7 days	'5 years 2 months 23 days
Volatility rate	44.00%	46.00%	47.00%
Dividend rate	0.00%	0.00%	0.00%

StockBased_Compensation_Summar

Stock-Based Compensation - Summary of Status of Stock Option Activity (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'
Beginning Balance, Number of Shares	3,600	3,417	3,166
Beginning balance, weighted average exercise price per share	$13.15	$12.60	$12.25
Granted, Number of Shares	529	624	617
Exercised, Number of Shares	-642	-351	-151
Cancelled, Number of Shares	-13	-90	-215
Ending Balance, Number of Shares	3,474	3,600	3,417
Vested and Expected to Vest, Number of Shares	3,280	'	'
Exercisable, Number of Shares	2,038	'	'
Available for future Grant, Number of Shares	1,683	'	'
Granted, weighted average exercise price per share	$22.36	$15.23	$13.61
Exercised, weighted average exercise price per share	$12.16	$11.85	$7.93
Cancelled, weighted average exercise price per share	$10.61	$11.94	$13.56
Ending balance, weighted average exercise price per share	$14.74	$13.15	$12.60
Vested and expected to vest, weighted average exercise price per share	$14.49	'	'
Exercisable, weighted average exercise price per share	$12.76	'	'
Weighted Average Remaining Contractual Term (in years)	'6 years 6 months 29 days	'	'
Vested and Expected to Vest, Weighted Average Remaining Contractual Term	'6 years 5 months 16 days	'	'
Exercisable, Weighted Average Remaining Contractual Term	'5 years 4 months 24 days	'	'
Aggregate intrinsic Value	$44,127	'	'
Vested and Expected to Vest, Aggregate Intrinsic Value	42,464	'	'
Exercisable, Aggregate Intrinsic Value	$29,918	'	'

StockBased_Compensation_Summar1

Stock-Based Compensation - Summary of Status of Stock Awards Activity (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'
Beginning Balance, Shares	522	502	351
Granted, Shares	74	145	235
Vested, Shares	-141	-107	-39
Forfeited, Shares	-1	-18	-45
Ending Balance, Shares	454	522	502
Beginning Balance, Weighted Average Grant Date Fair Value	$13.87	$13.65	$14.02
Granted, Weighted Average Grant Date Fair Value	$23.53	$15.69	$13.70
Vested, Weighted Average Grant Date Fair Value	$23.43	$15.29	$15.22
Forfeited, Weighted Average Grant Date Fair Value	$15.26	$13.81	$13.29
Ending Balance, Weighted Average Grant Date Fair Value	$16.22	$13.87	$13.65

Commitments_and_Contingencies_1

Commitments and Contingencies - Commitments for Minimum Rentals under Non-cancelable Leases (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'	'
Operating Leases, 2014	$2,363	'
Operating Leases, 2015	1,529	'
Operating Leases, 2016	2,007	'
Operating Leases, 2017	1,620	'
Operating Leases, 2018	1,441	'
Operating Leases, Thereafter	4,983	'
Operating Leases, Minimum Payments, Total	13,943	'
Lease Obligation, 2014	1,125	'
Lease Obligation, 2015	1,134	'
Lease Obligation, 2016	1,145	'
Lease Obligation, 2017	1,152	'
Lease Obligation, 2018	1,161	'
Lease Obligation, Thereafter	2,190	'
Lease Obligation, Minimum Payments, Total	7,907	'
Less amount representing interest	-2,340	'
Present value of lease obligation	5,567	'
Less current portion	-441	-380
Long-term lease obligation	$5,126	'

Commitments_and_Contingencies_2

Commitments and Contingencies - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

Oct. 31, 2013

Sep. 30, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2011

Oct. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Lease

Athens [Member]

Ohio [Member]

San Diego [Member]

San Diego [Member]

Santa Clara [Member]

Property Subject to Operating Lease [Member]

Property Subject to Operating Lease [Member]

Patented technology [Member]

License agreements [Member]

License agreements [Member]

Research and Development Collaboration Agreements [Member]

Claims and litigation [Member]

Claims and litigation [Member]

Lease

Lease

sqft

sqft

Sale Leaseback Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Rent expense under operating leases

'

'

$2,300,000

$2,000,000

$1,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Area under new operating lease

'

'

'

'

'

'

'

'

'

'

30,000

11,000

'

'

'

'

'

'

Lease expiration year

'

'

'2022

'

'

'2017

'

'

'

'

'

'

'

'

'

'

'

'

Number of extension

2

'

'

'

'

'

2

'

3

'

'

'

'

'

'

'

'

'

Extend the lease options

'5 years

'

'

'

'

'

'5 years

'

'5 years

'

'

'

'

'

'

'

'

'

Lease incentives for tenant improvements

'

'

1,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cease use charge

'

'

900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Lease term period

'

'

'

'

'

'

'

31-Oct-13

1-Dec-19

30-Nov-14

'

'

'

'

'

'

'

'

Facility sold

'

'

15,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Capital contributed

'

'

3,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash transaction, netting

'

'

7,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Partnership that acquired the facility

'

'

25.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amended terms

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

General partner's interest

'

'

'2015-01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Lease payments

'

'

1,100,000

1,100,000

1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase commitments

'

'

6,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued in other current liabilities

'

'

7,640,000

8,241,000

'

'

'

'

'

'

'

'

'

'

'

'

300,000

300,000

Agreement for payments totaling

'

'

29,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash payment

'

13,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fixed cash payment

'

15,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contract value Discount

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assigned licensed technology

'

'

'

'

'

'

'

'

'

'

'

'

28,800,000

'

'

'

'

'

One-time charge to cost of sales

'

'

700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization expense

'

'

16,600,000

15,400,000

11,300,000

'

'

'

'

'

'

'

'

8,000,000

8,000,000

'

'

'

Company recorded of royalty expense prior to the buy-out

'

'

'

'

4,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Terms of Amendment provide for an estimated useful life

'

'

'3 years 6 months

'

'

'

'

'

'

'

'

'

'

'5 years 10 months 24 days

'

'

'

'

Company had royalty and license expenses relating to those agreements

'

'

1,000,000

1,400,000

1,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Current commitments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,300,000

'

'

Industry_and_Geographic_Inform2

Industry and Geographic Information - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenue, Major Customer [Line Items]	'	'	'
Number of reportable segments	1	'	'
Customer Concentration Risk [Member] | Non-U.S. Customers [Member]	'	'	'
Revenue, Major Customer [Line Items]	'	'	'
Accounts receivable	3.2	2.8	'
Customer Concentration Risk [Member] | Sales [Member]	'	'	'
Revenue, Major Customer [Line Items]	'	'	'
Percentage of risk concentration by major customer	32.00%	34.00%	32.00%
Customer Concentration Risk [Member] | Sales [Member] | Non-U.S. Customers [Member]	'	'	'
Revenue, Major Customer [Line Items]	'	'	'
Percentage of risk concentration by major customer	13.00%	14.00%	14.00%
Credit Concentration Risk [Member]	'	'	'
Revenue, Major Customer [Line Items]	'	'	'
Accounts receivable	19.6	22.4	'
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Minimum [Member]	'	'	'
Revenue, Major Customer [Line Items]	'	'	'
Percentage of risk concentration by major customer	10.00%	10.00%	'

Industry_and_Geographic_Inform3

Industry and Geographic Information - Sales to Individual Customers in Excess of 10% of Total Revenue (Detail) (Sales [Member], Customer Concentration Risk [Member])	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenue, Major Customer [Line Items]	'	'	'
Sales percentage	32.00%	34.00%	32.00%
Customer A [Member]	'	'	'
Revenue, Major Customer [Line Items]	'	'	'
Sales percentage	15.00%	16.00%	15.00%
Customer B [Member]	'	'	'
Revenue, Major Customer [Line Items]	'	'	'
Sales percentage	17.00%	18.00%	17.00%

Industry_and_Geographic_Inform4

Industry and Geographic Information - Long-lived Assets (Excluding Intangible Assets) and Total Net Revenue (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Long-lived assets, Total	$48,057	'	'	'	$34,156	'	'	'	$48,057	$34,156	'
Total revenues	50,170	33,539	29,706	61,995	53,925	32,998	30,858	37,960	175,410	155,741	158,603
Federal [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Long-lived assets, Total	47,891	'	'	'	34,156	'	'	'	47,891	34,156	'
Total revenues	'	'	'	'	'	'	'	'	152,711	134,239	137,096
Foreign [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Long-lived assets, Total	166	'	'	'	'	'	'	'	166	'	'
Total revenues	'	'	'	'	'	'	'	'	$22,699	$21,502	$21,507

Industry_and_Geographic_Inform5

Industry and Geographic Information - Consolidated Net Product Revenues by Disease State (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting Information [Line Items]	'	'	'
Revenues	$175,410	$155,741	$158,603
Infectious Disease [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Revenues	128,079	110,982	112,227
Women's Health [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Revenues	33,328	32,653	32,715
Gastrointestinal Disease [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Revenues	6,622	6,328	6,920
Royalty, License Fees and Grant Revenue [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Revenues	3,917	2,452	2,419
Other Disease [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Revenues	$3,464	$3,326	$4,322

Fair_Value_Measurement_Assets_

Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Assets:	'	'
Total assets measured at fair value	$3,056	$11,000
Liabilities:	'	'
Total liabilities measured at fair value	8,808	5,000
Senior Credit Facility [Member]	'	'
Liabilities:	'	'
Total liabilities measured at fair value	'	5,000
Cash equivalents [Member]	'	'
Assets:	'	'
Total assets measured at fair value	3,056	11,000
Contingent consideration [Member]	'	'
Liabilities:	'	'
Total liabilities measured at fair value	8,808	'
Level 1 [Member]	'	'
Assets:	'	'
Total assets measured at fair value	3,056	11,000
Liabilities:	'	'
Total liabilities measured at fair value	'	'
Level 1 [Member] | Senior Credit Facility [Member]	'	'
Liabilities:	'	'
Total liabilities measured at fair value	'	'
Level 1 [Member] | Cash equivalents [Member]	'	'
Assets:	'	'
Total assets measured at fair value	3,056	11,000
Level 1 [Member] | Contingent consideration [Member]	'	'
Liabilities:	'	'
Total liabilities measured at fair value	'	'
Level2 [Member]	'	'
Assets:	'	'
Total assets measured at fair value	'	'
Liabilities:	'	'
Total liabilities measured at fair value	'	5,000
Level2 [Member] | Senior Credit Facility [Member]	'	'
Liabilities:	'	'
Total liabilities measured at fair value	'	5,000
Level2 [Member] | Cash equivalents [Member]	'	'
Assets:	'	'
Total assets measured at fair value	'	'
Level2 [Member] | Contingent consideration [Member]	'	'
Liabilities:	'	'
Total liabilities measured at fair value	'	'
Level 3 [Member]	'	'
Assets:	'	'
Total assets measured at fair value	'	'
Liabilities:	'	'
Total liabilities measured at fair value	8,808	'
Level 3 [Member] | Senior Credit Facility [Member]	'	'
Liabilities:	'	'
Total liabilities measured at fair value	'	'
Level 3 [Member] | Cash equivalents [Member]	'	'
Assets:	'	'
Total assets measured at fair value	'	'
Level 3 [Member] | Contingent consideration [Member]	'	'
Liabilities:	'	'
Total liabilities measured at fair value	$8,808	'

Fair_Value_Measurement_Additio

Fair Value Measurement - Additional Information (Detail) (USD $)	144 Months Ended
In Millions, unless otherwise specified	Dec. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'
Amount outstanding under the Senior Credit Facility	'	$0	$5
Loss recorded in research and development due to change in fair value of contingent consideration liabilities	0.1	'	'
Money Market Funds [Member] | Level 1 [Member]	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'
Carrying value of cash equivalents	'	$3.10	$11

Fair_Value_Measurement_Changes

Fair Value Measurement - Changes in Estimated Fair Value of Contingent Consideration Liabilities (Detail) (Level 3 [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Balance	'
Cash payment	-947
Losses recorded for fair value adjustments	80
Unrealized loss on foreign currency translation	6
Balance	8,808
BioHelix [Member]	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Acquisition	9,355
Andiatec [Member]	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Acquisition	$314

Employee_Benefit_Plan_Addition

Employee Benefit Plan - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Compensation Related Costs [Abstract]	'	'	'
Pay contributed by employer	50.00%	'	'
Pay contributed by employee	6.00%	'	'
Contribution to 401 (K) Plan	$0.90	$0.80	$0.80

Acquisitions_Additional_Inform

Acquisitions - Additional Information (Detail) (USD $)	12 Months Ended						0 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Aug. 26, 2013	Aug. 26, 2013	Aug. 26, 2013
			BioHelix [Member]	BioHelix [Member]	BioHelix [Member]	BioHelix [Member]	Andiatec [Member]	Andiatec [Member]	Andiatec [Member]
					Minimum [Member]	Maximum [Member]		Research and Development Milestones [Member]	Maximum [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'
Cash consideration	'	$1,000,000	$10,000,000	'	'	'	'	'	'
Net cash consideration	9,184,000	'	9,184,000	'	'	'	'	'	'
Contingent consideration	'	'	9,355,000	'	5,000,000	13,000,000	300,000	4,000,000	700,000
Payment of contingent consideration	947,000	'	'	'	'	'	'	'	'
Current portion of contingent consideration	1,493,000	'	'	'	'	'	'	'	'
Contingent consideration non-current portion	7,315,000	'	'	'	'	'	'	'	'
Goodwill	80,763,000	71,013,000	8,850,000	'	'	'	900,000	'	'
Transaction costs in conjunction with acquisition	'	'	300,000	'	'	'	200,000	'	'
Impacted on basic and diluted earnings per share	$0.01	'	$0.20	$0.12	'	'	'	'	'
Cash payments to acquire assets	2,250,000	'	'	'	'	'	2,300,000	'	'
Acquisition hold back	'	'	'	'	'	'	400,000	'	'
Intangible assets	'	'	'	'	'	'	1,800,000	'	'
Other assets	'	'	$683,000	'	'	'	$300,000	'	'

Acquisitions_Allocation_of_Pur

Acquisitions - Allocation of Purchase Price to Net Tangible and Intangible Assets Acquired and Liabilities (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Cash consideration	'	$1,000
Net cash consideration	9,184	'
Goodwill	80,763	71,013
BioHelix [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cash consideration	10,000	'
Settlement of pre-existing liabilities and working capital adjustment	-816	'
Net cash consideration	9,184	'
Contingent consideration	9,355	'
Net consideration at closing	18,539	'
Other current and non-current assets	683	'
Property, plant and equipment	179	'
Goodwill	8,850	'
Total assets acquired	24,772	'
Accounts payable and other current liabilities	730	'
Deferred tax liabilities	5,503	'
Total liabilities assumed	6,233	'
Purchase price allocation	18,539	'
BioHelix [Member] | In-process research and development [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Fair Value of Finite-lived Intangible Asset	690	'
BioHelix [Member] | Purchased technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Fair Value of Finite-lived Intangible Asset	4,340	'
Weighted-average amortization period	'10 years	'
BioHelix [Member] | Non-compete agreement [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Fair Value of Finite-lived Intangible Asset	700	'
Weighted-average amortization period	'5 years	'
BioHelix [Member] | Contractual relationships [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Fair Value of Finite-lived Intangible Asset	530	'
Weighted-average amortization period	'10 years	'
BioHelix [Member] | Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Fair Value of Finite-lived Intangible Asset	$8,800	'
Weighted-average amortization period	'12 years	'

Acquisitions_Schedule_of_Pro_F

Acquisitions - Schedule of Pro Forma Financial Information (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Pro forma diluted net earnings (loss) per share	'	'	'	'	'	'	'	'	$0.01	'	'
Total revenue included in the consolidated statements of operations	'	'	'	'	'	'	'	'	$175,410	$155,741	$158,603
Net loss included in the consolidated statements of operations	1,139	-4,361	-1,755	12,367	8,740	-676	-3,122	51	7,390	4,993	7,633
BioHelix [Member]	'	'	'	'	'	'	'	'	'	'	'
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Pro forma total revenues	'	'	'	'	'	'	'	'	176,359	158,071	'
Pro forma net income (loss)	'	'	'	'	'	'	'	'	6,900	3,987	'
Pro forma basic net earnings (loss) per share	'	'	'	'	'	'	'	'	$0.20	$0.12	'
Pro forma diluted net earnings (loss) per share	'	'	'	'	'	'	'	'	$0.20	$0.12	'
Total revenue included in the consolidated statements of operations	'	'	'	'	'	'	'	'	596	'	'
Net loss included in the consolidated statements of operations	'	'	'	'	'	'	'	'	($1,505)	'	'

Selected_Quarterly_Financial_D2

Selected Quarterly Financial Data (unaudited) - Quarterly Financial Data (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Statement [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	$50,170	$33,539	$29,706	$61,995	$53,925	$32,998	$30,858	$37,960	$175,410	$155,741	$158,603
Cost of sales (excludes amortization of intangible assets)	18,461	15,297	13,671	19,547	17,597	14,872	14,008	14,808	66,976	61,285	62,865
Gross profit	30,126	16,695	14,524	41,010	34,890	16,688	15,412	21,714	'	'	'
Total costs and expenses	50,103	39,507	36,829	44,806	39,808	34,220	35,377	37,490	171,245	146,895	144,863
Net income (loss)	$1,139	($4,361)	($1,755)	$12,367	$8,740	($676)	($3,122)	$51	$7,390	$4,993	$7,633
Basic net earnings (loss) per share	$0.03	($0.13)	($0.05)	$0.37	'	'	'	'	$0.22	$0.15	$0.23
Diluted net earnings (loss) per share	$0.03	($0.13)	($0.05)	$0.36	'	'	'	'	$0.21	$0.15	$0.23
Basic and diluted net income (loss) per share	'	'	'	'	$0.26	($0.02)	($0.09)	$0	'	'	'

Selected_Quarterly_Financial_D3

Selected Quarterly Financial Data (unaudited) - Quarterly Financial Data (Parenthetical) (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012
Income Statement [Abstract]	'	'	'	'	'	'	'	'
Amortization of intangible assets included in gross profit	$1.70	$1.50	$1.50	$1.40	$1.40	$1.40	$1.40	$1.40

Consolidated_Valuation_and_Qua1

Consolidated Valuation and Qualifying Accounts (Detail) (Allowance for Doubtful Accounts [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Allowance for Doubtful Accounts [Member]	'	'	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Beginning Balance	$4,955	$1,960	$1,882
Charges to costs and expenses	15,230	10,849	7,909
Charges to other accounts	'	'	'
Deductions	-14,395	-7,854	-7,831
Ending Balance	$5,790	$4,955	$1,960